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ABSTRACT
ABIN1 IN THE PATHOGENESIS OF GLOMERULONEPHRITIS AND THE NOVEL
PODOCYTE-NEUTROPHIL PROINFLAMMATORY AXIS
Erik Anderson Korte
April 8th, 2016

Glomerulonephritis (GN) is the most common cause of end-stage renal disease
worldwide and is characterized by deposition of immune complex, inflammation,
proteinuria and podocyte damage. Immunosuppressive therapy is effective in less than
50% of patients, indicating that immunological activity is not the only relevant cause of
kidney injury. While methods have been described for neutrophil-mediated immune
activation, specific glomerular mechanisms for recruitment of neutrophils and
development of GN have not been determined.
Here I present a pathogenic mechanism for the development of GN involving a
novel podocyte-neutrophil axis and reveal the importance of glomerular NF-κB inhibition
by the ubiquitin binding protein, ABIN1.

I implicate enhanced glomerular NF-κB

activity in human chronic kidney disease using transcriptomic analysis and link genetic
ABIN1 polymorphisms to increased risk of lupus-related GN.

Mice expressing

dysfunctional ABIN1 with disrupted polyubiquitin binding activity are shown to develop
spontaneous, progressive glomerular disease. Prevention and early diagnosis require an
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understanding of the initiating steps of disease pathogenesis, so early pathogenic changes
were examined using antibodies directed against the mouse glomerular basement
membrane to induce rapid glomerular damage.

Glomeruli of mice expressing

dysfunctional ABIN1 exhibit increased production of NF-κB target cytokines and rapid
induction of GN versus wild type mice.

Bone marrow transplantation reveals the

glomerular genotype is more critical than the immune genotype following insult, further
supporting the role of the target tissue in early disease pathogenesis. I outline the
contributions of mass spectrometry to the discovery of modulating factors and disease
biomarkers in autoimmunity and describe an optimized technique to characterize the
secreted protein milieu of cultured human podocytes. Dysfunctional ABIN1 results in
enhanced cytokine production by podocytes that can recruit and activate primary
neutrophils.

Further, the podocytes are more sensitive to pathogenic cytoskeletal

remodeling following exposure to neutrophil granules, highlighting a reciprocal injurious
mechanism. Finally, a novel peptide inhibitor of neutrophil granule release attenuates
antibody-induced proteinuria in these mice and may have therapeutic potential in human
GN. Thus, I describe a novel podocyte-neutrophil axis in the pathogenesis of GN and
propose a potential molecular mechanism of GN involving loss of ABIN1 function
resulting in excessive NF-κB activation.
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CHAPTER I

BACKGROUND AND INTRODUCTION

1.1 – Overview

The basic role of the kidney is to provide selective filtration of blood for removal
of wastes, homeostatic maintenance of vascular solutes, and regulation of blood volume.
Together, the kidneys receive roughly 25% of cardiac output. This high rate of perfusion
is required for optimal renal function and reduction in the glomerular perfusion results in
reduced renal function.

The renal arterial vasculature terminates at a small ball of

capillaries termed the glomerulus which is where initial filtration takes place. Damage to
the glomerulus results in protein and/or whole cell loss into the urine and reduced renal
function [1]. Glomerulonephritis (GN) is a term which represents a heterogeneous group
of diseases which accounts for 20% of chronic kidney diseases and is the leading cause of
end-stage renal disease (ESRD) worldwide, although it ranks third in the United States
behind diabetes and hypertension [2]. While GN is rather rare, unlike diabetes and
hypertension, it predominantly affects young people and results in a lifelong medical
burden for the patient and the health system.
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Many of the conditions clustered under the grand title of GN share a similar
etiology, that is, deposition of antibodies within the glomerulus.

These circulating

antibodies may deposit in the glomerulus through passive means with low or no direct
affinity to the glomerular structures, which is the case in Lupus Nephritis (LN) and IgA
nephropathy[1,3,4].

In some cases, these antibodies are specific for glomerular

structures, as in Goodpasture disease as well as membranous glomerulonephritis
(formerly “Idiopathic” GN before identification of the Phospholipase A2 receptor as the
autoantigenic target of membranous glomerulonephritis in our lab in 2009) [5–7].
It can be argued that the archetypical autoimmune condition throughout medical
history is systemic lupus erythematosus (SLE), characterized by an abnormal immune
response leading to loss of self-tolerance, autoantibody production, immune complex
formation, T cell activation, and inflammatory cytokine release [8]. Medical historians
note writings by Hippocrates that refer to the condition, but it was not until the late
1800’s and early 1900’s when it was described in the modern sense [9]. Multiple factors
contribute

to

the

immune

response

in

SLE

including

genetic,

epigenetic,

immunoregulatory, environmental, and hormonal factors [8,9]. SLE has the ability to
affect essentially any body tissue, including the kidney.
Lupus nephritis (LN) occurs clinically in about 50% of patients with SLE and is a
major cause of morbidity and mortality [10]. The incidence of LN is variable among
different ethnic groups suggesting that genetic factors play a role in its pathogenesis.
Primarily, individuals of African ancestry are at increased risk for LN [4].
Immunosuppressive treatment is effective in only about 50% of LN patients, and that
therapy is associated with undesirable short- and long-term side effects [11–14]. Thus,
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identifying the molecular mechanisms responsible for the pathogenesis of LN is
necessary to define more specific diagnostic and therapeutic targets. Such understanding
may provide biomarkers of disease state which would enable treatment to be
administered most effectively along with assessment of positive response to therapy such
that the treatment can be modified or stopped in a timely manner to best manage adverse
side effects.
These markers also provide important pathogenic insight and tools for testing new
or improved therapeutics. Historically, SLE was diagnosed based solely on clinical
features (i.e. rash, arthritis) and only recent times have seen the development of
quantifiable diagnostic markers for laboratory confirmation of clinical findings by
measurement of immune cell profiles and activity, identification of specific
autoantibodies, and identification of changes in protein expression profiles in bodily fluid
(i.e. urine, blood, cerebral spinal fluid) [9].

Traditional approaches to biomarker

discovery allowed only limited numbers of identified proteins per sample which,
unfortunately, required an initial selection bias on the part of the researcher. Recent
improvements in mass spectrometry based approaches to novel biomarker discovery have
allowed a level of insight not previously possible through the identification of thousands
of proteins from individual samples. Mass spectrometry-based studies aimed at defining
diagnostic markers for SLE complications by comparing protein expression in normal
and diseased bodily fluids have used two basic approaches; 1) assessment of protein
expression differences from stained 2D gels followed by MALDI-TOF/TOF
identification of the proteins in differing spots or 2) direct assessment and comparison of
protein expression from intrinsic LC-MS/MS data [8, 10]. The total picture of SLE and
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LN diagnosis, however, is still incredibly complex and interactions of genetic risks,
environmental factors, and molecular events that contribute to the development of LN are
only beginning to be defined.
Finally, novel discoveries involving the molecular mechanisms behind LN
pathogenesis, in particular the early events surrounding the inflammatory cascade which
takes place following antibody deposition within the glomerulus, have the potential to
contribute to the understanding of other antibody-mediated glomerulonephropathies.
While outcomes and long term histological changes may differ due to systemic or local
differences in these conditions, many share the same acute initiating event involving
glomerular antibody deposition, and thus novel therapies directed at inhibiting pathogenic
changes in this earliest stage of disease may find utility across the GN
spectrum[1,3,5,7,12,15]. For a more complete understanding of the events following
antibody deposition within the glomerulus, we must first discuss the cellular anatomy of
the kidney and the current physiological understanding of the cell types involved in the
glomerular response to damage.

1.2 – Renal Anatomy and the Cellular Pathogenesis of Glomerular Inflammation

The functional unit of the kidney is the nephron (Figure 1). The glomerular
capillaries serve as a size- and charge-dependent filtration barrier and are contained
within the Bowman’s capsule which also includes non-capillary volume (Bowman’s
space) for collection of the ultrafiltrate upon exiting the glomerular capillaries. Upon
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Figure 1 – The Nephron
The nephron is the functional unit of the kidney. The glomerular ball is held within the
Bowman’s Capsule which drains into the proximal convoluted tubule, which begins the
Loop of Henle, tasked with concentrating the urine before exit into the distal
convoluted tubule and eventual draining into the collection duct which empties into the
renal pelvis.
Copyright Permissions not required for this type of use.
http://open.umich.edu/education/med/resources/second-look-series/materials
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exiting the Bowman’s space, the ultrafiltrate is concentrated and modified by cells lining
the tubular walls. The direction of flow is as follows: the proximal convoluted tubule 
descending limb of the loop of Henle  ascending limp of the loop of Henle  distal
convoluted tubule  and finally the collecting duct which drains the concentrated urine
into the renal pelvis. Pathologies have been reported at almost every point in the nephron
and possess a multitude of instigating factors and as well as promising therapeutics [16].
However, the instigating factors in GN are almost invariably involving the glomerulus
itself, which is where we now turn our focus.
Three cell types are predominant within the glomerulus: endothelial cells,
mesangial cells, and podocytes. Figure 2 illustrates the arrangement of glomerular tissue.
Endothelial cells line the endothelial side of the glomerular capillaries. Mesangial cells
produce and maintain a significant portion of the extracellular matrix that supports the
glomerulus. And finally, the epithelial podocytes are situated outside of the glomerular
capillaries and critically support the glomerular capillary basement membrane.
Podocytes accomplish this feat through cellular projections called foot processes, which
interdigitate tightly to wrap the basement membrane. Small gaps between foot processes
are called slit diaphragms and are very highly regulated by expression of membrane
spanning proteins as well as intracellular structures and the actin cytoskeleton. Figure 3
diagrams this anatomy in a healthy glomerulus. Figure 3a shows regularly spaced foot
processes with well-defined slit diaphragms separating them. Figure 3b describes a
number of critical proteins involved in maintaining the slit diaphragm, namely nephrin
and the underlying actin cytoskeleton itself. In pathologic conditions involving antibody
deposition leading to inflammatory damage within the glomerulus, foot process structure

6

Figure 2 – Diagram of Glomerular Structures
A – Bowman’s Capsule, B – Proximal convoluted tubule, C – Distal convoluted tubule,
D – Juxtaglomerular apparatus, 1. Basement membrane (Basal lamina), 2. Bowman's
capsule – parietal layer, 3. Bowman's capsule – visceral layer, 3a. Pedicels (Foot
processes from podocytes), 3b. Podocyte, 4. Bowman's space (urinary space), 5a.
Mesangium – Intraglomerular cell, 5b. Mesangium – Extraglomerular cell, 6. Granular
cells (Juxtaglomerular cells), 7. Macula densa, 8. Myocytes (smooth muscle), 9. Afferent
arteriole, 10. Glomerulus Capillaries, 11. Efferent arteriole
Illustration by : Michał Komorniczak
Copyright Permissions not required for this type of use
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A.

B.

Figure 3 - The Podocyte Slit Diaphragm Structures
The podocyte slit diaphragm is an intensely maintained glomerular structure which is
formed by the gap between podocytes foot processes. Loss of foot process structure is a
common sign of glomerular pathology. (a) TEM image of cross section of GBM with slit
diaphragm highlighted within the box. (b) Illustration of known slit diaphragm proteins.
Of particular note in this figure is the association of f-actin of the podocyte cytoskeleton
in the maintenance of the slit diaphragm.
Maddalena Gigante, Matteo Piemontese, Loreto Gesualdo, Achille Iolascon, and Filippo Aucella, “Molecular and Genetic Basis of
Inherited Nephrotic Syndrome,” International Journal of Nephrology, vol. 2011, Article ID 792195, 15 pages, 2011.
doi:10.4061/2011/792195
Copyright Permissions not required for this type of use
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changes as outlined in Figure 4. Regularly-spaced slit diaphragms on the epithelial side
of the glomerulus are lost as foot processes efface, fuse, form pseudocysts, and
potentially detach from the glomerular capillary completely [17].
It has been shown that mesangial cells respond to immunoglobulin, complement
and cytokines by producing various cytokines and chemokines, resulting in increased
endothelial cell expression of adhesion molecules that recruit and activate leukocytes
[15,18,19].

Podocytes, too, are important factors in the glomerular inflammatory

response, although they are markedly understudied. It is known that inflammatory injury
leads to podocyte dysfunction, podocyte damage is a primary cause of proteinuria, and
podocyte loss into the urine may be a better marker for glomerular injury than proteinuria
[17,20,21]. Only a handful of published works have investigated the possibility of a
direct role of podocytes in the induction of GN. Hewins et al. reported that IL-18 is
expressed by podocytes in biopsies from patients with ANCA-associated vasculitis [22].
Kuravi et al. reported that TNF-α stimulated cultured podocytes to release IL-6, resulting
in inhibition of leukocyte adhesion to vascular endothelial cells [23]. Yet, the response of
podocytes to immunoglobulin and/or complement deposition and their contribution to the
inflammatory response remain markedly understudied.

These studies suggest that

podocytes may participate in providing the cytokines and chemokines that control
glomerular inflammation and further understanding of how the podocyte interacts with
the immune system as well as the local tissue may provide pathogenic clues to more
effective treatment or earlier diagnosis of poorly responding patients.
In contrast to the unknown role of podocytes, neutrophils have long been
implicated in the pathogenesis of antibody-mediated GN, albeit recent studies tend to
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Figure 4 - Foot Process Pathologies Following Injury
The podocyte foot process is structurally sensitive to damage, and many insults can result
in loss of foot process structure. Diseased glomeruli frequently exhibit foot process
effacement, pseudocyst formation and bare areas of the GBM.
Illustration by Erik Korte, unpublished.
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focus primarily on the role of monocytes, B-cells, T-cells, and dendritic cells [23–29].
Neutrophils can release both reactive oxygen species and proteases contained in
neutrophil granules have been reported to be responsible for degradation of the
glomerular basement membrane and subsequent proteinuria [25–27]. Direct podocyte
injury by neutrophils has not previously been evaluated. A recent report by Devi et al.
showed that the glomerulus is a unique capillary bed that is constitutively patrolled by
neutrophils which are retained within the glomerulus in the absence of proinflammatory
stimulation [28].

Glomerular inflammation induced by deposition of anti-GBM

antibodies increased the neutrophil retention time by 3- to 4-fold without increasing the
number of neutrophils entering the glomerulus. Retention of neutrophils within the
glomerulus, even in cases without proinflammatory stimulation, provides the opportunity
for intimate interaction with local cells. Due to the prolonged retention of neutrophils in
the glomerular capillaries, it is possible that small changes in localized expression of
proinflammatory cytokines and chemokines may play a part in the induction of neutrophil
activation in local tissues. Until this point, little has been known regarding the cytokine
milieu secreted by podocytes and thus their role in disease pathogenesis. The work
presented in this dissertation seeks to describe these unknown processes in renal
pathophysiology.

1.3 – Nuclear Factor kappa B in Inflammation and Disease

11

The transcription factor nuclear factor-kappa B (NF-κB) regulates the expression
of hundreds of genes that control cell proliferation and survival, the cellular stress
response, innate immunity, and inflammation. Dysregulation of NF-κB activity is
associated with many human diseases, especially those involving chronic inflammation,
and recent studies suggest that NF-κB plays a role in the incidence and severity of GN as
well [30–34]. In particular, both mesangial cells and podocytes demonstrate NF-κB
activation and cytokine production in response to proinflammatory mediators [35–37].
Immunohistochemistry (IHC)-based studies have shown enhanced glomerular and tubular
expression of NF-κB, NF-κB regulatory proteins, and NF-κB target pro-inflammatory
cytokines in renal biopsies from LN patients, compared with normal controls and patients
with minimal change disease [33,34].

Another report found that pharmacological

inhibition of NF-κB reduced the development of autoantibodies and renal impairment in
SLE susceptible FcγRIIb-deficient mice [30]. Treatment of spontaneous SLE developing
SWRxNZB mice with a flavonoid, Apigenin, inhibited NF-κB mediated events in T cells
and suppressed serum IgG levels resulting in delayed appearance of nephritis [31]. This
inhibition of NF-κB signaling protects against development of disease, at least in part,
through reduced expression of cytokines that are transcriptional targets of NF-κB (TNFα, IL-1β, IL-8, MCP-1, etc.) [30,33,34,38].
NF-κB is activated by a variety of immune, inflammatory, and stress stimuli
through many cytokine and toll-like receptors (TLR) and regulated through a complex
interplay of proteins (recently reviewed in [39]). Figure 5 provides a general outline of
the pathway. In resting cells, NF-κB is sequestered in the cytoplasm in an inactive state
by binding to Inhibitor of κB (IκB) proteins [40,41]. Following activation, the IκB is
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Figure 5 - NF-κB Activation
In the canonical NF-κB pathway, the transcription factor dimer is sequestered in the
cytoplasm by IκB.

Phosphorylation and polyubiquitination of IκB results in its

proteosomal degradation and translocation of NF-κB to the nucleus.

This is

accomplished by an Inhibitor kappa Kinase (IKK) complex which includes an α, β, and γ
subunit. The γ subunit is called NEMO and is activated through linear or lysine-63
linked polyubiquitination by numerous upstream factors in the Inflammatory Activation
Complex (IAC).
Illustration by Erik Korte, unpublished.
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phosphorylated, polyubiquinated through Lys48 linkages, and then degraded by the
proteasome. This releases an active NF-κB complex to translocate to the nucleus and
drive target gene expression. In the canonical NF-κB pathway, phosphorylation of IκB is
mediated by the IκB kinase (IKK) complex, which consist of α, β, and γ subunits [42].
IKKγ is the regulatory subunit also referred to as NF-κB essential modulator (NEMO).
Activation of IKK is mediated by an IKK Activating Complex (IAC), a diverse group of
signaling proteins which includes TRAFs, RIPs, TAKs and IRAKs, and is assembled
through protein-protein interactions to linear and lysine 63-linked and linear
polyubiquitin chains and interacts with the linking protein MyD88 in TLR-mediated
pathways [43–46]. NEMO binding to head-to-tail linked linear polyubiquitin chains or
the Linear Ubiquitin Assembly Complex (LUBAC) also activates the canonical NF-κB
pathway [44,47,48]. Tight regulatory control is required for NF-κB signaling to prevent
excessive production of many proinflammatory mediators.

1.4 – ABIN1 as a Regulator of NF-κB Signaling

The ubiquitin-binding protein, A20 binding inhibitor of NF-κB 1 (ABIN1), was
first described in 1999 by Heyninck et al using a yeast two-hybrid screen and defined as a
novel inhibitor of NF-κB and important A20 interacting partner [49]. She later described
the structure and function of ABIN1, making note of the sequence homology of the
ubiquitin bindings domains (UBD) of ABIN1 and NEMO [50]. Initial mouse models
reported conflicting results when ABIN1 expression was knocked out, resulting in
14

embryonic lethality due to excessive liver apoptosis [51]. This embryonic lethality could
be resolved through co-knockdown of the TNF-α receptor 1 alongside ABIN1,
highlighting the importance of ABIN1 inhibition in the regulation of TNF-α induced
signaling pathways [52]. Our lab returned to the original work of Heyninck et al to
examine the homology between NEMO and ABIN1 as it pertains to autoimmunity and
found that polyubiquitin binding to lysine 63-linked and linear polyubiquitin chains (as
well as lysine 48-linked to a lesser degree) is required to prevent spontaneous immune
hyperactivation in mice [53].
It is now clear that ABIN1 has important inhibitory roles for NF-κB signaling
related to its ability to bind polyubiquitinated proteins and modulate their function [52–
55]. Figure 6 depicts ABIN1-mediated inhibition of a general NF-κB pathway. ABIN1
binds to lysine 63-linked and linear polyubiquitin chains and contains the same UBD as
NEMO that facilitates binding to other regulatory proteins, such as TRAF2/6, RIP1,
IRAK1 and others [47,52,53,56–58]. It is not clear how ABIN1 inhibits NF-κB activity,
but two possible mechanisms have been proposed: the first is that ABIN1 binding
competes with NEMO binding to proteins required for activation of IKK, and the second
is that ABIN1 recruits A20 to the IKK regulatory complex where A20 disrupts the
interactions needed for IKK activation by removing lysine 63-linked or linear
polyubiquitin moieties from regulatory proteins [59,60]. A20 has also been reported to
mediate proteasomal degradation of ubiquitin processing proteins that mediate IKK
activation [61]. Asp (D) to Asn (N) mutation at residue 485 (mouse) or 472 (human) of
the UBD renders ABIN1 incapable of binding polyubiquitin chains on NF-κB activators
and is similar to the homologous [D311N] mutation in NEMO [44,50,51,53,62]. We
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Figure 6 – ABIN1-mediated Inhibition of NF-κB Signaling
ABIN1 can bind polyubiquitinated substrates through its ubiquitin-binding domain
(UBD).

IKKγ

(NEMO) is

activated

through

lysine-63

linked

and

linear

polypolyubiquitin binding as are many factors in the IAC. ABIN1 binding may recruit
A20 which can remove ubiquitin moieties from target proteins to inhibit their
downstream functions.
Illustration by Erik Korte, unpublished.
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reported that a knock-in mouse in which wild type ABIN1 was replaced by
ABIN1[D485N] induced constitutive activation of NF-κB signaling leading to elevated
cytokine production and development of a progressive SLE-like autoimmune disease
[53]. Renal injury in these animals was not characterized in this report.

1.5 – Discovering a Protective Role for ABIN1 in Glomerular Disease Pathogenesis

As outlined above, glomerular disease progression is highly associated with NFκB activation and NF-κB expression in podocytes is also tied to potentially destructive
phenotypes.

Podocyte injury is made more severe by loss of nephrin in the slit

diaphragm, which itself is known to inhibit NF-κB signaling, and NF-κB signaling in
general has been shown to increase during progression to end-stage renal disease [63,64].
It has been reported that expression of NF-κB proteins in podocytes was positively
correlated to the severity of podocyte injury and subsequent proteinuria [33]. Genome
wide association studies of American, European and Chinese SLE patients identified
polymorphisms in ABIN1 which increased risk for developing disease [65–69]. What we
currently know about ABIN1 suggests that it may have a role in the pathogenesis of
glomerular disease.

Therefore, we hypothesize that functional ABIN1 expressed in

glomerular tissue, particularly in podocytes, is critical for maintenance of the glomerular
microenvironment, control of local inflammation, and preservation of proper renal
function.
This dissertation will present data showing that ABIN1 is, in fact, critical to
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proper glomerular inflammatory homeostasis. Novel mass spectrometry methods for
characterization of ABIN1 phenotypic changes to podocytes will highlight the
importance of proper NF-κB signaling regulation within podocytes. By using ubiquitin
binding deficient ABIN1 in vivo and in vitro, the importance of functional ABIN1 to
glomerular function will be described. Human polymorphisms in the ABIN1 locus will
be defined as specific risk factors for development of glomerular disease. Pathological
studies of tissue and cultured podocytes will define the role of ABIN1 in podocyte
function.

And a novel proinflammatory axis that exists between podocytes and

neutrophils will be defined as a potential initiating step in the pathogenesis of antibodymediated GN. Finally, an inhibitor of neutrophil degranulation will be described with
these models as a possible therapeutic treatment for early stages of glomerular disease.
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CHAPTER II

MATERIALS AND METHODS

2.1 – Overview

Experimental characterization of intricate biological function requires numerous
methods and rigorous, well-controlled experimental design. This presented a daunting
challenge. I designed in vivo, in vitro, and ex vivo experiments capable of parsing the
complex interplay of the immune system with a target tissue with a wide possibility of
potential mechanisms, if any mechanism did in fact exist, to explain my hypothesis. My
experimental design aimed to disprove my hypothesis and, failing that, shed light on the
potential role of ABIN1 in the pathogenesis of glomerulonephritis.

2.2 – Molecular Biology and Genetic Protocols

Polymerase Chain Reaction – DNA amplification for cloning or analysis was performed
on a CFX96 thermocycler (BioRad) or an EdvoCycler Model 541 (EdvoTek).
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AccuPrime PFX (Invitrogen) was the polymerase and standard PCR master mixes were
used (Invitrogen).

Reaction parameters were according to the manufacturer’s

specifications: 3 minutes at 95 °C, followed by 30 cycles of 94 °C for 30 seconds,
annealing at 50 °C for 30 seconds, extension at 72 °C for 30 seconds, with a final
extension at 72 °C for 3 minutes.

Bacterial Transformation – One Shot TOP10 Chemically Competent E. coli (Invitrogen)
were utilized for transformation of bacterial stocks. Stocks of chemically competent cells
were mixed with 200 μg plasmid DNA on ice for 30 minutes followed by a 30 second
heat shock in a 42 °C water bath, then return to ice for 2 minutes. SOC media was added
to the cells and they were incubated at 37 °C for 1 hour. Transformed bacteria were then
transferred to LB agar plates containing either Ampicillin (100 μg/mL) or Kanamycin (50
μg/mL) to match the resistance markers on the plasmid and incubated overnight at 37 °C.
The following morning, single colonies were selected and grown in LB broth (Fisher
Scientific) overnight at 37 °C with gentle agitation at 300 RPM. After 16-18 hours, the
bacteria were pelleted through centrifugation at 5000 x g for 10 minutes and plasmid
isolated as described below.

Plasmid Preparation – Plasmid preparation was accomplished using the Qiagen Mini
Prep Kit or the Qiagen Maxi Prep Kit depending on the amount of plasmid needed
(Qiagen, MD). The mini kit was sufficient for purification from 2-5 mL LB broth at high
turbidity. The mega kit was sufficient for purification from up to 100 mL LB broth at
high turbidity.
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Restriction Enzyme Digest – All restriction digests utilized in the course of this
dissertation used enzymes from New England Biolabs which was also the source for all
buffers and BSA (as required). Restriction digests were held at a static temperature
(typically 37 °C) in an EdvoCycler (EdvoTek) if in a 50 μL or smaller volume, or in a
water bath calibrated to 37 °C (Fisher Scientific).

Agarose Gel Electrophoresis – DNA amplicon, purified RNA or digested plasmid were
run on 1% agarose gels to separate the DNA fragments by size using a 1kb Plus DNA
Ladder (Invitrogen) or a 10kb Plus DNA Ladder (Invitrogen) as appropriate. Agarose
gels were produced fresh using 1g powdered agarose (BioRad) per 100 mL 1x TAE
buffer (BioRad). Standard gels comprised 50mL total volume and could be scaled up or
down depending on specific needs of the sample. One volume of glycerol-based (5%
final concentration) DNA loading buffer was mixed 4 volumes of sample and current was
applied at an appropriate level for an appropriate amount of time to achieve sufficient
separation of the dye bands from the starting lane. Visualization of the DNA bands was
achieved using Ethidium Bromide (Shelton Scientific) and UV excitation and digital
image capture on the ChemiDoc MP (BioRad).

RNA Isolation –RNA was isolated from various tissues using the Aurum Total RNA Mini
Kit (Qiagen). Appropriate volumes of starting samples were lysed with the lysis buffer,
mixed 1:1 with RNA-grade Ethanol (Sigma) and bound to Aurum Mini Columns
(Qiagen) for washing in proprietary buffers. Following the second wash, a 15 minute
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DNase protocol degraded genomic DNA, the final wash was applied, and purified RNA
was isolated in RNase-free water. Quantification of RNA was achieved by readings in
duplicate or triplicate on a NanoDrop 2000c spec (Thermo).

All protocols using

interaction with RNA required RNase-free materials, including tips, tubes and reagents.
Great care was taken to prevent introduction of exogenous RNases from the environment.
Many RNA samples were checked for sample integrity using gel electrophoresis and
ethidium bromide staining as described above to assess a 2:1 ratio of staining for 28S and
18S bands, respectively, with properly sharp lines. This could be done post hoc and
samples of RNA were always saved until completion of the experiment in case questions
arose about sample integrity.

Reverse Transcription of cDNA – Purified RNA was reverse transcribed into cDNA using
the iScript Reverse Transcription Supermix for RT-qPCR which employed a proprietary
blend of oligo (dT) and random primers to provide unbiased representation of both 5’ and
3’ regions of transcript (BioRad). Optimal conditions allowed 1 μg of template RNA in
16 μL RNA eluate, combined with 4 μL 5x Supermix, to allow a 20 μL reaction volume
as required. If RNA concentrations for the experiment were not sufficient in ALL
samples to produce 1 μg template RNA in 16 μL reaction volume, all samples in the
experiment were scaled down to a minimum input of 200 ng RNA per sample. This
range was determined to be optimal in our lab for our transcript targets using our
equipment and is not intended discount the much wider ranges published by BioRad.
The 20 μL final reaction volume could be scaled up to produce additional cDNA if
experimental design called for more. Reverse transcription was performed on a CFX96
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thermocycler (BioRad) or an EdvoCycler Model 541 (EdvoTek). Each sample was
mixed on ice and cycling parameters were as follows: priming at 25 °C for 5 minutes,
reverse transcription at 42 °C for 30 minutes, and enzyme inactivation at 85 °C for 5
minutes, followed by a static hold at 4 °C. cDNA was used immediately or stored at -20
°C with limited freeze/thaws in this final RT solution using the protocol volumes
described below.

Primer Preparation – Primers for RT-qPCR were prepared using the database and
software Primer-BLAST (NCBI) and selected custom primers were produced by
Invitrogen (Carlsbad, CA).

PCR product size was optimized for the transcript but

generally was limited to 70-300 bp based on cycling parameters and Tm was optimized
for each transcript as well. Multiple primer pairs were produced and tested for every
transcript and for potential off target effects or primer dimers by melt-curve analysis on
all analyzed samples.

Primers which spanned introns were preferred to reduce

interference of contaminate genomic DNA.

Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) – iTaq Universal SYBR
Green Mastermix (BioRad) was used at 1x in a final reaction volume of 20 μL per well of
a 96-well RT-qPCR plate (BioRad). Each reaction included a final concentration of 0.4
μM forward and 0.4 μM reverse primers optimized to be effective at that concentration
for simplicity, and 1 μL of output cDNA from the reverse transcription protocol. Only on
rare instances were these parameters changed. SYBR green was used for its low cost and
simplicity in primer design, although the potential for off target amplification required a
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melt curve analysis with each run. Thermocycling was performed on a CFX96 (BioRad).
Following a 2 minute activation at 95 °C, 40 cycles were completed of denaturation at 95
°C for 15 seconds followed by annealing and extension at 60 °C for 40 seconds. The
melt curve analysis progressed from 65 °C to 95 °C in 0.5 °C steps with 5 seconds per
step. Housekeeping genes were optimized for each experiment but were typically either
GAPDH or 18s rRNA, depending on stimulant and concentration of target. Fold changes
were calculated using the ΔΔCt method.

Genome-Wide Association Study – A total of 16,999 independent case and control
samples were collected from multiple sites as part of the Large Lupus Association Study
2 (LLAS2) with the Institutional Review Board (IRB) approval from each institution and
processed at the Oklahoma Medical Research Foundation (OMRF) under the auspices of
the OMRF institutional review board. Only individuals who signed informed consent
forms were included in the study. All SLE cases met the revised 1997 American College
of Rheumatology for classification of SLE. Among SLE cases, those with lupus nephritis
fulfilled the renal criterion of either (1) persistent proteinuria >0.5 g per day (24 h) or
persistent >3+ if quantification was not performed or (2) presence of urinary cellular
casts (Table 2). All SLE cases met the revised 1997 American College of Rheumatology
for classification of SLE [70]. Among SLE cases, those with lupus nephritis fulfilled the
renal criterion of either (1) persistent proteinuria >0.5 g per day (24 h) or persistent >3+ if
quantification was not performed or (2) presence of urinary cellular casts [70]. The
custom-design Illumina iSelect platform at OMRF was used to genotype 5 SNPs in
TNIP1 previously reported to be associated with systemic sclerosis (rs4958881,
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rs3792783, rs2233287) [71], SLE (rs7708392) [67], psoriasis (rs3762999, rs999556,
rs17728338) [72,73], and psoriatic arthritis (rs17728338, one of psoriasis SNPs) [74]. In
addition, 347 ancestral-informative markers (AIMs) spanning the genome were
genotyped. After application of quality controls by excluding samples if they exhibited
low call rates (<90%) and extreme heterozygosity (>5 standard deviations from the
mean), revealed discrepancies between reported gender and genetic data, or were
determined to be a duplicate or cryptic related to another sample (the proportion of alleles
shared identical by descent >0.4), and removing extreme population outliers based on
global ancestry estimation and principal component analysis (calculated using the AIMs
in the ADMIXMAP[75,76] and EIGENSTRAT[77] programs, respectively) as described
in other LLAS2 reports [66,78], a final dataset of 15,864 unrelated subjects was obtained.
Single marker association analyses were calculated using the logistic regression function
in PLINK v1.07 [79]. The additive genetic model was applied while adjusting for gender
and global ancestry estimates (African, European, and East Asian) [66,80,81].

The

Bonferroni corrected p-value threshold was set to P < 0.01 based on multiple tests of 5
SNPs.

2.3 – Plasmids and Lentiviral Transduction

pCMV6-AC-mGFP – This cloning system was purchased from Origene to produce GFPtagged ABIN1 in cultured cells at a higher level than endogenous ABIN1 was produced.
A cytomegalovirus (CMV) promoter on the cassette accomplished this in all cell types
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used. This plasmid also conferred ampicillin resistance for selection and high level
production in bacterial cultures. An insert sequence was produced and sent to Origene
for production. Plasmid sequences were confirmed before being used and both GFP and
ABIN1 proteins were recognized appropriately by all methods employed in the course of
this study.

pCMV6-AC-DDK – This cloning system was produced as the GFP tagged system above,
but rather than GFP, it included a DDK tail (non-proprietary FLAG system) for protein
purification.

Lentiviral Transduction using MDM00734 pCSC-SP-PW – Some cells are resistant to
transient transfection due to sensitivity to transfective agents or other reasons, thus
Lentiviral transduction was used as an alternative, which produces stable expression of
target proteins in difficult to transfect cells. This plasmid was designed by Michael
Mendenhall of the University of Kentucky Viral Core. With the help of Dr. Mendenhall,
we designed a protocol for isolating ABIN1 inserts of the appropriate genotype (WT and
ABIN1[D472N] and others) from transfection plasmids and production of lentivirus
capable of transduction of cultured podocytes. Per the University of Louisville IRB
Approval, no virus was reproduced in University of Louisville facilities. All local viral
stocks were replication deficient. An optimized multiplicity of infection (MOI) of 1-10
based on viral titer was used for each cell type and optimized to achieve equal expression
of WT, ABIN1[D472N] or other genotype. Lentiviral stocks were aliquoted, frozen for
transport and thawed only once at 37 °C on the day of use. Cells grown in 6-well dishes
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(TTP) in 2 mL appropriate cell culture media were exposed to an appropriate volume of
lentivirus in polybrene at 8 μg/mL (a kind gift of Dr. Mendenhall). Following an 8 hour
incubation, media was removed and a second volume of 2 mL media with virus and 8
μg/mL polybrene was added and allowed to infect overnight. Fresh media was applied
and cells were allowed to grow for 72 hours before transduction could be checked via
fluorescence microscopy on an inverted CKX41 (Olympus). Expression was confirmed
via RT-qPCR, sequencing, western blot and other methods.

2.4 – Antibodies

ABIN1 – For detection of ABIN1, a mouse monoclonal antibody (Santa Cruz – sc376999) was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight
at 4 degrees followed by goat-anti-mouse-HRP (Santa Cruz – sc-2005) at 1:2000 (200
μg/mL stock) for 1 hour at room temperature and chemiluminescent using Clarity
Western ECL Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and
ImageLab 3.0 Software (Biorad).

MCP-1/CCL2 – For detection of MCP-1, a mouse monoclonal antibody (Santa Cruz – sc377082) was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight
at 4 degrees followed by goat-anti-mouse-HRP (Santa Cruz – sc-2005) at 1:2000 (200
μg/mL stock) for 1 hour at room temperature and chemiluminescent using Clarity
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Western ECL Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and
ImageLab 3.0 Software (Biorad).

GAPDH – For detection of GAPDH, a rabbit polyclonal antibody (Santa Cruz – sc25778) was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight
at 4 degrees followed by goat-anti-rabbit-HRP (Santa Cruz – sc-2004) at 1:2000 (200
μg/mL stock) for 1 hour at room temperature and chemiluminescent using Clarity
Western ECL Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and
ImageLab 3.0 Software (Biorad).

ET-1 – For detection of Endothelin 1, a goat polyclonal antibody (Santa Cruz – sc-21625)
was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight at 4
degrees followed by rabbit-anti-goat -HRP (Santa Cruz – sc-2768) at 1:2000 (200 μg/mL
stock) for 1 hour at room temperature and chemiluminescent using Clarity Western ECL
Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and ImageLab 3.0
Software (Biorad).

ERK 1 – For detection of ERK 1, a rabbit polyclonal antibody (Santa Cruz – sc-94) was
used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight at 4 degrees
followed by goat-anti-rabbit-HRP (Santa Cruz – sc-2004) at 1:2000 (200 μg/mL stock)
for 1 hour at room temperature and chemiluminescent using Clarity Western ECL
Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and ImageLab 3.0
Software (Biorad).
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IκBα – For detection of IκBα, a rabbit polyclonal antibody (Santa Cruz – sc-847) was
used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight at 4 degrees
followed by goat-anti-rabbit-HRP (Santa Cruz – sc-2004) at 1:2000 (200 μg/mL stock)
for 1 hour at room temperature and chemiluminescent using Clarity Western ECL
Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and ImageLab 3.0
Software (Biorad).

p-IκBα – For detection of phosphorylated-IκBα, a rabbit polyclonal antibody (Santa Cruz
– sc-101713) was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS
overnight at 4 degrees followed by goat-anti-rabbit-HRP (Santa Cruz – sc-2004) at
1:2000 (200 μg/mL stock) for 1 hour at room temperature and chemiluminescent using
Clarity Western ECL Substrate (BioRad) on the BioRad ChemiDoc MP Image Station
and ImageLab 3.0 Software (Biorad).

Podocin – For detection of podocin, a rabbit polyclonal antibody (Santa Cruz – sc-21009)
was used at 1:200 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight at 4
degrees followed by goat-anti-rabbit-HRP (Santa Cruz – sc-2004) at 1:2000 (200 μg/mL
stock) for 1 hour at room temperature and chemiluminescent using Clarity Western ECL
Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and ImageLab 3.0
Software (Biorad).

p-ERK – For detection of phosphorylated ERK, a mouse monoclonal antibody (Santa
Cruz – sc-7383) was used at 1:100 dilution (200 μg/mL stock) in 5% milk in 1x TTBS
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overnight at 4 degrees followed by goat-anti-mouse-HRP (Santa Cruz – sc-2005) at
1:2000 (200 μg/mL stock) for 1 hour at room temperature and chemiluminescent using
Clarity Western ECL Substrate (BioRad) on the BioRad ChemiDoc MP Image Station
and ImageLab 3.0 Software (Biorad).

A20 – For detection of A20, a mouse monoclonal antibody (Santa Cruz – sc-376564) was
used at 1:100 dilution (200 μg/mL stock) in 5% milk in 1x TTBS overnight at 4 degrees
followed by goat-anti-mouse-HRP (Santa Cruz – sc-2005) at 1:2000 (200 μg/mL stock)
for 1 hour at room temperature and chemiluminescent using Clarity Western ECL
Substrate (BioRad) on the BioRad ChemiDoc MP Image Station and ImageLab 3.0
Software (Biorad).

β-actin – For detection of β-actin for use as a loading control, a mouse monoclonal
antibody conjugated to HRP (Santa Cruz – sc-47778-HRP) was used at 1:500 dilution
(200 μg/mL stock) in 5% milk in 1x TTBS for 1 hour at room temperature and
chemiluminescent using Clarity Western ECL Substrate (BioRad) on the BioRad
ChemiDoc MP Image Station and ImageLab 3.0 Software (Biorad).

2.5 – Cell Culture

Conditionally Immortalized Podocytes – In 2002, Moin Saleem published his
characterization of a conditionally immortalized podocyte cell line using a temperature
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sensitive SV40-T-gene that revolutionized almost all modern research into podocyte
biology [82]. Briefly, these cells grow permissively at 33 °C, but upon exposure to 37 °C
temperatures for 7-10 days, they enter growth arrest and express markers of differentiated
podocytes in vivo.

These cells were grown in RPMI-1640 without glutamine

(Invitrogen), supplemented with 1x Pen/Strep/Glutamine (Invitrogen), 10% fetal bovine
serum (Sigma), and 1x Insulin/Transferrin/Selenium-X (Invitrogen). Many stimulants
were used, but this dissertation focuses on TNF-α (100ng/mL) (BioLegend) for all cell
culture work.

Podocyte Actin Labeling and Confocal Microscopy – Confocal microscopy images were
obtained as previously described[83].

Briefly, 35mm collagen-coated glass bottom

dishes (MatTek) were seeded with podocytes and allowed to mature at 37 °C for 10 days.
Cells were serum starved with 0.5% FBS medium 24 h before stimulant was added.
Following stimulation, cells were rinsed three times with PBS that contained calcium and
magnesium and fixed in 3.7% paraformaldehyde (Azer Scientific) in PBS (Invitrogen) for
10 min, followed by permeabilization with 0.025% NP-40 (Sigma) in PBS for 15 min and
washing. Cells were blocked in 5% BSA (Sigma) in PBS for 30 minutes before addition
of 200 μL (3 units) rhodamine-phalloidin (Thermo) for 30 minutes. Following another
wash, 300 nM DAPI (Invitrogen) was incubated for 5 min, and rinsed three times with
PBS, mounted using Vectashield Antifade Mounting Medium for Fluorescence (Vector
Labs). Images were acquired using a Zeiss confocal microscope and analyzed using
LSM510 software. The images for rhodamine were analyzed by FibrilTool as
recommended by the published protocol[84].
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2.6 – General Protein Expression Assays

Sample Preparation and Cellular Lysis – Cultured cells were washed 3 times with icecold PBS and lysed in RIPA Buffer (Sigma) containing 1x Protease Inhibitor Cocktail
(Sigma) and 1x Phosphatase Inhibitor Cocktail (Santa Cruz). Lysis was allowed to
proceed on ice for 30 minutes followed by a centrifugation at 20,000 x g for 30 minutes
at 4 °C to pellet cellular debris. An appropriate volume of lysis buffer was used to
accommodate either the confluency of cells on the plate or the approximate size of the
cell pellet.

Protein Quantification – Protein concentration was estimated using the BCA method
(Thermo) in triplicate according to the manufacturer’s protocol. Lysis buffer or vehicle
into which the sample is diluted was used as a blank and serial dilutions of BCA
(Thermo) were used to generate a standard curve.

SDS-PAGE – Appropriate volumes of protein sample and water were added to 5x
Laemmli Sample Buffer (final concentration 60 mM Tris-Cl pH 6.8, 2% SDS, 10%
glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue) to achieve equal estimated
loading of all samples to be loaded in the gel. Mini-PROTEAN TGX pre-cast 4-20%
gradient gels (BioRad) were immersed in 1x Tris-Glycine-SDS buffer (BioRad) and run
under constant voltage (15-250V) deemed appropriate for desired time of separation or
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size of target proteins. Precision Plus Dual Color protein standard (BioRad) was used to
gauge size of bands identified in western blot protocol (in kDa).

Polyvinylidene Fluoride (PVDF) Transfer – PVDF (BioRad) was used rather than
nitrocellulose. PVDF was rehydrated for at least one minute in 100% methanol (Sigma)
followed by at least 10 minutes in 1x Tris-Glycine transfer buffer (BioRad). Semi-dry
transfer was achieved using the Trans-Blot Turbo (BioRad) at appropriate current
(usually 300 mA but varied based on sample). Totality of transfer was assessed by
staining the gel post-transfer with Coomassie stain for 15 minutes followed by 1-4 hours
of destain in 40% methanol (Sigma) and 10% acetic acid (Sigma).

Western Blotting – PVDF membrane was washed 3 times in 1x TTBS followed by >30
minute block in 5% milk (Great Value) in TTBS. Appripriate dilutions of primary and
secondary antibodies were added to 5% milk in TTBS. Primary antibodies were allowed
to bind overnight at 4 °C with rocking, followed by 3 washes in 1x TTBS. HRPconjugated secondary antibodies were allowed to bind for 1 hour at room temperature
with gentle rocking before washing 3 times in 1x TTBS. Chemiluminescent detection
was achieved using Clarity Western ECL Substrate (BioRad) on the BioRad ChemiDoc
MP Image Station and ImageLab 3.0 Software (Biorad).

Enzyme-Linked Immunosorbent Assay (ELISA) – Secreted cytokine levels for MCP-1, IL8, and TNF-α were analyzed using the BioLegend ELISA Max Deluxe kits per the
manufacturer protocol.

To allow secretome samples to be utilized with primary
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neutrophils, samples were stimulated for 6 hours with TNF-α followed by 3 washes in
sterile, endotoxin-free Krebs buffer, followed by a 6 hour collection in 10mL Krebs
buffer per 10cm dish at 70% confluence.

This stimulation and wash regimen was

determined to be optimal for the cytokines of interest and no detectable TNF-α remained
following the 3 wash steps (<<2pg/mL).

Luminex-based Cytokine Arrays – Blood was collected from mice by cardiac puncture,
allowed to clot, and the serum was separated by centrifugation. Cytokines in mouse
serum were measured using the Bio-Plex Mouse Cytokine 23-plex assay on the Bio-Plex
MAGPIX Multiplex reader according to the manufacturer’s protocol (Bio-Rad).

2.7 – Mass Spectrometry Based Protein Detection

Label-free Sequencing and Quantification of Total Protein – Briefly, protein
concentration was estimated using the BCA method (Thermo, Rockford, IL), diluted with
6M urea in 100 mM ammonium bicarbonate, reduced with dithiothreitol and alkylated
with iodoacetamide. The sample was digested using sequence-grade trypsin at a 1:100
ratio of trypsin to sample protein and incubated overnight at 37 °C with shaking, then
desalted and concentrated using a fused silica microcapillary C-18 column (Michrom
Bioresources, Auburn, CA). The resulting peptides were analyzed by a Thermo Fisher
Scientific LTQ-Orbitrap Elite mass spectrometer coupled with a Proxeon Easy nanoLC
1000 UHPLC system (Thermo, Rockford, IL). Protein identification was performed with
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Sequest Sorcerer (Sage-N Research, San Jose, CA), set up to search a FASTA formatted
human protein database (Human RefSeq). High-probability peptide and protein
assignments were made using Peptide and Protein Prophet algorithms[85]. Abundance of
each identified protein was determined by normalizing the number of unique spectral
counts matching to the protein by its predicted molecular weight, termed the protein
abundance factor [5,86,87].

Cytokine production by unstimulated ABIN1 WT-

expressing podocytes was defined as the normal cytokine secretome and was compared to
the ABIN1 WT stimulated and both stimulated and non-stimulated ABIN1[D472N]
dataset to identify changes to the normal secretome of these cells.

Secretome Identification, Size Selective – Most cytokines are small proteins and we have
found that sample purity is increased through a 10 minute centrifugation in an Amicon
Ultra-30kDa Centrifugal Filter Unit (Millipore, Billerica, MA) to remove proteins larger
than 30 kDa, followed by preparation as we have previously described.

2.8 – Animal Handling and Assays for Primary Tissue

Transgenic Mice – The ABIN1[D485N] global knockin mice were generated on a
129SvJxC57BL/6 background[53] and then backcrossed eight generations to C57BL/6
for the present studies.

Heterozygous mice were used to generate ABIN1[D485N]

homozygous and littermate WT control mice for all the experiments. Female mice from
0-6 months of age were utilized as indicated. All animals were maintained in specific
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pathogen free conditions and all studies were approved by the Institutional Animal Care
and Use Committee of the University of Louisville (Louisville, KY).

Bone Marrow Transplant and Development of Chimeric Animals – Bone marrow
transplant was carried out as previously described[88]. Briefly, 5-7 week old female
mice were conditioned with 950 cGy total body irradiation from a caesium source
(Gamma-cell 40; Nordion, Ontario, Canada). At 24 h post irradiation, the mice were
transplanted with bone marrow cells (1 x 107 cells per mouse in 0.1 ml PBS) isolated
from tibias and femurs of age-matched donor mice, through the retro-orbital plexus with
a 27-gauge needle. Ten WT mice received WT bone marrow and ten received
ABIN1[D485N] bone marrow. Likewise, ten ABIN1[D485N] mice received WT bone
marrow and ten received ABIN1[D485N] bone marrow. Engraftment was allowed to
proceed for 5-7 weeks before administration of α-GBM. Engraftment was confirmed
using leukocytes isolated from whole blood. Both the recipient and donor mice were
maintained on normal chow throughout the experiment.

Urine Albumin:Creatinine Measurements – Spot urine samples were captured by
scruffing the mice and massaging the bladder over a clean, disposable surface and
collected in a sterile microcentrifuge tube. Urine was centrifuged at 5000 x g for 5
minutes then standard sandwich ELISA was performed in triplicate according to the
manufacturer’s protocol for mouse albumin (Bethyl) and a kinetic Jaffe method for
creatinine (Thermo).

The ratio of albumin (μg/mL) and creatinine (mg/mL) was

calculated for each sample at each time point.
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Serum C3 Quantification – Serum was collected from ABIN1[D485N] and WT mice at
ages 3-4 months and 5-6 months. C3 measurements were performed using a 1:25,000
dilution of mouse serum and measurement with the Mouse C3 ELISA Kit from GenWay
Biotech (#40-374-130047) per the manufacturer’s guidelines. All samples were tested in
duplicate and the average was reported.

Histopathology and immunohistochemical staining of mouse cortical tissue – Formalinfixed, paraffin embedded tissues were stained with PAS reagent for histological analysis
by light microscopy. Glomerular damage was assessed by semiquantitative scoring of
cellularity and mesangial matrix expansion on a 0 (normal), 1+ (mild abnormality), 2+
(moderate abnormality), and 3+ (severe abnormality) scale. For immunohistochemical
labeling of proteins, sections were deparaffinized in xylene and rehydrated in graded
alcohols. Antigen retrieval was achieved using citrate buffer solution for 20 minutes at
95 °C (Dako), slides were washed in buffer and endogenous peroxidases were quenched
with H2O2 for 5 minutes before washing and a 30 minute block in buffer containing 5%
BSA and 2% sera at RT. Primary antibody was applied overnight at 4 °C and 1:200
dilution for WT-1 (Santa Cruz), CD45 (Angio-Proteomie), 1:50 dilution for MPO
(AbCam) or with buffer only as a negative control followed by washing and incubation
with appropriate secondaries at 1:200 dilution. All sections including negative controls
were then incubated with respective biotinylated secondary antibodies (1:200, Vector
Labs), followed by incubation in avidin/biotinylated enzyme complex (Vectastain Elite
ABC kit, Vector Labs). Proteins were detected following color development using 3,3′-
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diaminobenzidine (DAB) as substrate (Vector Labs). Counterstaining was performing
using hematoxylin (Vector Labs) and cells were dehydrated, mounted and viewed at
100x. Digital Images were obtained with a Q Color 5 camera attached to an Olympus
BX51 microscope using Image-Pro software.

Immunofluorescence – For immunofluorescent analysis of C3, IgA or IgM, 4 micron
frozen sections were first washed in PBS 3x5 minutes each. The blocking solution was
applied for 30 minutes at room temperature. The primary antibody was then added for 2
hours at room temperature. The sections were washed for 5 minutes in PBS three times.
FITC primary antibody (C3- Cedar Lanes Laboratory, IgG- Sigma Aldrich, C1q- Hycult
Biotech) or unlabeled primary antibody (IgA-Invitrogen, IgM-Invitrogen) followed by
florescent secondary antibody (Alexa Flour 555- Invitrogen) were used. Following
antibody incubation, slides were washed in PBS 3x5 minutes. Images were acquired
using a Zeiss confocal microscope and analyzed with LSM510 software.

Transmission Electron Miscroscopy – Freshly dissected cortical tissue was placed in a
cryomold with OCT compound (Tissue-Tek) and flash frozen in liquid nitrogen. Thick
(1-mm) sections were prepared to evaluate the orientation and presence of glomeruli.
Thin sections were mounted on 200 mesh naked copper grids and stained with lead citrate
and uranyl acetate (4% in absolute alcohol). Sections were prepared for electron
microscopy by postfixing in osmium, dehydrating in an alcohol series, and embedding in
Durcupan resin (Ted Pella, Redding, CA) and imaging via a CM10 transmission electron
microscope (Phillips).
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Therapeutic Caffeination of Researcher – To achieve sufficient levels of cognition to
conform to University of Louisville Occupational Health and Safety guidelines, daily
consumption of 3-5 aliquots of 8.5g prepared dark blend or similar ground coffee bean
(Caza Trail or similar) was performed on a B70 Platinum Brewing System (Keurig)
followed by supplementation with 72 mg saccharine (Cumberland Packing Corporation).
Physiological changes were monitored and dosing modified as necessary.

Glomerular purification – To obtain 95% pure glomeruli for RNA extraction, we utilized
a common sieving technique in small batches. Briefly, renal cortex is dissected and
minced followed by collagenase treatment (Sigma), initial filtration through 100nm nylon
mesh (VWR) and glomerular purification and washing with Hanks Buffer (Invitrogen) in
a 70nm nylon mesh (VWR). Glomerular samples obtained were determined to be at least
90% glomeruli by light microscopy with <5% tubule contamination.

Purification of Primary Neutrophils from Donor Blood – The Percoll method is a
standard density gradient capable of separating cellular components of whole blood.
Briefly, whole blood from donors was centrifuged at 500 x g for 35 minutes at 25 °C,
with neutrophils forming a distinct band which can be purified. Isolated neutrophils were
diluted in endotoxin-free, sterile Krebs buffer. Microscopic evaluation of isolated cells
showed that >92% of cells were neutrophils. Trypan blue exclusion indicated that >95%
of cells were viable. The Institutional Review Board of the University of Louisville
approved the use of human donors who provided informed consent.
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Stimulation of Primary Neutrophils and Isolation of Granule Contents – Neutrophil
granule contents were produced by stimulating donor neutrophils with TNF-α (2 ng/mL)
(Sigma) and 300 nM N-Formyl-Met-Leu-Phe (fMLF) (Sigma) for 30 minutes at 37 °C in
Krebs buffer. Neutrophil cell bodies were removed via centrifugation for 5 minutes at
5000 x g.

Neutrophil Chemotaxis – Donor neutrophils were resuspended at 5 x 104 in Krebs buffer
and 100 μL of suspended PMNs were allowed to undergo chemotaxis per manufacturer
guidelines into 6.6mm diameter and 3μM pore size Transwell Permeable Supports
(Corning) using a 1:600 dilution of cell culture supernatant in sterile, endotoxin-free
Krebs buffer. The Hema 3 protocol (Fisher) was used to fix and stain the membranes.

Neutrophil Degranulation – Degranulation of specific and azurophilic granules was
determined by measuring binding of FITC-conjugated monoclonal anti-CD35
(Pharmingen) and FITC-conjugated monoclonal anti-CD66b (Accurate Chemical) on 4 ×
106/ml neutrophils using a FACSCalibur flow cytometer (Becton Dickinson, Franklin
Lakes, N.J., USA) as previously described[89].

Nephrotoxic Sera and TAT-SNAP23 Administration – Nephrotoxic sera (a kind gift of Dr.
David Salant) or control sera (Rockland) was injected into the tail vein of mice at
1.5mg/25g mouse body weight. TAT-SNAP23 was produced by Dr. Kenneth McLeish.
Briefly, human neutrophil SNAP23 was cloned into a pTAT-vector and expressed DH5a
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competent cells (Invitrogen).

E. coli BL21-AI cells (Invitrogen) were used to

overexpress the recombinant TAT fusion proteins which were purified by Ni-NTA beads
(Invitrogen). Administration of TAT-SNAP23 was via tail vein injection at the time of αGBM administration and 6 hours after administration at a concentration of 0.05mg/kg
body weight.
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CHAPTER III

PROTEOMIC APPLICATIONS FOR DEFINING CELLULAR MECHANISMS AND
DIAGNOSTIC MARKERS OF SYSTEMIC LUPUS ERYTHEMATOSUS

3.1 – Overview of mass spectrometry and discovery proteomics

As described in the Introduction, autoimmune diseases such as systemic lupus
erythematosus (SLE) can affect many different body systems, including the central
nervous system, blood cells, joints, skin, heart, lungs, and kidneys [11]. The molecular
mediators which promote disease pathogenesis are not fully known, thus a primary
objective of translational research is the identification of reliable, non-invasive, and
quantifiable markers for detection of the early-onset of specific complications. Such
markers would enable treatment to be administered most effectively along with
assessment of positive response to therapy such that the treatment can be modified or
stopped in a timely manner to best manage adverse side effects. These markers also
provide important pathogenic insight and tools for testing new or improved therapeutics.
In addition to clinical features (i.e. rash, arthritis), diagnostic information for SLE or GN
is also provided by measurement of immune cell profiles and activity, identification of
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specific autoantibodies, and identification of changes in protein expression profiles in
bodily fluid (i.e. blood, cerebral spinal fluid, lavage fluid, and importantly in GN, urine).
Mass spectrometry-based proteomic technologies have played an important role
in each area of clinical diagnosis as well as the development of a more comprehensive
understanding of the underlying disease process using a myriad of diverse sample types
and techniques.

One of the preferred mass spectrometry methods in proteomics

combines one or two dimensional (1D or 2D) liquid chromatography (LC) peptide
separation with electro-spray ionization (ESI) tandem mass spectrometry (MS/MS) [90].
This LC-MS/MS methodology allows for a direct and highly-sensitive identification of
hundreds of individual proteins from virtually any type of biomedical sample [91]. The
decision to use 1D versus 2D-LC is based on the complexity of the protein sample.
Typically SDS-PAGE bands or spots (< 30 proteins) are analyzed by 1D and much more
complex samples, such as affinity-purifications and whole cell, tissue, or bodily fluid
extracts are analyzed with 2D-LC-MS/MS. Another type of mass spectrometry that is
employed is matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF)
[92]. With this approach up to 96 individual protein samples are spotted onto a stationary
target for analysis. Although the sensitivity of MALDI-TOF is limited to characterizing
the 10-15 most abundant proteins in each sample, it has the benefit of being a higher
throughput platform for lower complexity, pre-fractionated protein mixtures (i.e. gel
separation) because each sample is analyzed in minutes where as a typical 1D-LC run
requires an hour and 2D-LC-MS/MS takes 10-12 hours. A third mass spectrometry
approach is surface-enhanced laser desorption/ionization-time of flight (SELDI-TOF), a
modification of MALDI-TOF [93]. With SELDI-TOF, different surface components,
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such as strong anion exchangers or hydrophobic characteristics, allow binding of proteins
with certain characteristics while dissimilar proteins are washed away. This allows
analysis of targeted subsets of structurally related proteins and reducing the complexity of
the sample improves the overall sensitivity or dynamic range of detection. SELDI-TOF
results differ from LC-MS/MS and MALDI-TOF/TOF in that the results are given in
mass to charge ratios (m/z) rather than peptide sequence, so positive protein identification
is not possible. It is, however, useful for rapid analysis of the protein m/z profiles of
semi-complex samples by reducing upfront separation while preserving the fast analysis
time of a MALDI platform. Although not as desirable for discovery, these attributes of
relative ease of sample preparation and speed of analysis and data output, as well as
lower startup and operation costs presents SELDI-TOF as a more suitable mass
spectrometry platform for a clinical test.
A key component of these studies is the method used to prepare selectively
targeted protein samples for mass spectrometry interpretation.

Auto-antigen

identification studies usually involve separation of the tissue of interest by 1D or 2D
electrophoresis (1-DE or 2-DE) SDS-PAGE, followed by immuno-blotting with anti-sera
from SLE patients, and identification of proteins in immune-reactive bands by MALDITOF/TOF or LC-MS/MS analysis [94]. Another approach isolates autoantibodies from
SLE patient serum using immobilized protein G which is then used to affinity enrich
antigens in targeted tissue extracts for direct characterization with 2D-LC-MS/MS
analysis [95]. As mentioned above, studies comparing diseased and healthy body fluids
use two general approaches; 1) 2D gel electrophoresis followed by staining of total
protein and MALDI-TOF/TOF identification of the proteins in differing spots or 2) direct
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comparison of total protein expression using LC-MS/MS [94,96]. The work flow of
these applications is described in Figure 7. Starting from sample, which could be any
preparation of proteins, work flow could lead to a number of separation/purification
techniques or proceed directly to tryptic digestion. Both 1-DE and 2-DE are used to
immunoblot for novel autoantigens followed by analysis, frequently MALDI or SELDI,
but also including 1D and 2D-LC-MS/MS. Complex samples may be separated by
affinity chromatography, immunoprecipitation or magnetic bead separation. Techniques
may be employed to remove primarily high-abundance proteins, separate based on
protein chemistry or interaction kinetics involving immunoglobulins or other proteins.
The digested peptides could be subjected to analysis by MALDI, SELDI, and 1D- or 2DESI-LC/MS/MS.

Gel separated and digested proteins are frequently analyzed with

MALDI or SELDI platforms, but are appropriate for ESI as well. More complex sample
types, in particular whole cell lysates, which have not been separated, are frequently
subjected to 1D- or 2D-LC peptide separation coupled with ESI-MS/MS analysis. The 2dimentional aspect of LC separation allows a greater number of proteins to be identified
from very complex samples when compared to the other methods, with the tradeoff being
the greatly increased time (10-12 hours) to analyze one sample. SELDI-TOF and
MALDI-TOF are used for profiling while MALDI-TOF-TOF and ESI-MS/MS can
sequence the peptides in the sample to positively identify their parent proteins.
Finally, we provide a mechanism by which LC-MS/MS was used to define the
proteome of cell culture supernatant which is later assessed for its ability to activate
primary neutrophils ex vivo.
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Figure 7 - Flowchart of LC-MS/MS Sample Preparation
Abbreviations:

1-DE,

One-Dimensional

Electrophoresis;

2-DE,

2-Dimentional

Electrophoresis; SELDI, Surface-Enhanced Laser Desorption/Ionization; MALDI,
Matrix-assisted

laser

desorption/ionization;

1D-LC,

One-Dimensional

Liquid

Chromatography; 2D-LC, Two-Dimensional Liquid Chromatography; TOF, Time-ofFlight; ESI, Electrospray Ionization
Korte, et al. 2012.
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Here I seek to explain prior contributions of mass spectrometry techniques to the
biological understanding, diagnosis and treatment of SLE, in particular LN, and to lay out
a framework for subsequent study of SLE, LN and GN. It is the hope of any investigator
that they can catalyze the dissemination of information to allow a greater understanding
of complex techniques and illustrate their potential in translational and clinical research
related to human diseases. Here I outline relevant contributions of LC-MS/MS and
discovery proteomics and adapt protocols which will be utilized to study glomerular
disease as described in Chapters IV and V.

3.2 – Cardiovascular systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is an autoimmune condition known to
increase a patient’s risk for cardiovascular disease (CVD). Even when correcting for
potentially confounding factors such as age, genetic background, treatment methodology,
family history, disease profile, etc., SLE patients have been shown to have risk up to 50
times above that predicted by Framingham Risk Factors [97–100]. While mortality rates
for active disease have fallen in recent decades, mortality rates for CVD in long-term
SLE patients continue to rise [97,100]. LN occurs in about 50% of SLE patients and is a
major cause of morbidity and mortality, with a significant component attributed to
increased risk of ischemic heart disease [10,101,102]. The genetic risks, environmental
factors, and molecular events that determine susceptibility for LN are unknown. A great
deal of effort has been put into understanding the changes to the cardiovascular system in
SLE. Cardiac involvement in SLE has been reported with prevalence up to 50% [103],
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but on average only 9% will develop true myocarditis [104,105]. SLE has long been
known to result in immune deposits in the pericardium and/or myocardium of SLE
patients, resulting in both histopathologic and gross anatomic changes [106].
Arrhythmias including sinus tachycardia, atrial fibrillation, long QT, atrioventricular
block and bundle branch block are rare complications, but can have significant effects
when combined with other factors such as antimalarial therapy [105] and studies have
reported up to 16% of children with SLE to have asymptomatic cardiovascular disease
[107]. The risk of developing coronary artery disease is 4-8 times higher in SLE patients
than in controls, and this risk increases to 50-fold in young women [98]. Treatment can
be tailored to specific patients at risk for the development of such complications, but for
this to be possible, early diagnosis of SLE is required followed by the accurate gauging of
cardiovascular risk. Mass spectrometry findings have been used to characterize the
proteomic changes in the SLE disease state to better understand the pathogenic
mechanisms behind cardiovascular disease to allow earlier diagnosis and improved risk
assessment [96,108–111]. Relevant results are summarized in Table 1.
To better understand pathogenesis of cardiovascular SLE and provide biomarkers
for prompt diagnosis, autoantigens involved in congenital heart block were subjected to
proteolytic cleavage with and without sera of SLE patients, followed by MALDI-TOFTOF identification of antibody-protected sites (epitopes) [110]. The resulting peptides
were found to correspond to the 200-239 amino acid portion of the Ro52 protein,
supporting the use of autoantibodies against Ro52 as a biomarker. Subsequent studies
have supported the role of anti-Ro antibodies (both Ro52 and Ro60) in congenital heart
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Table 1 – Contributions of Mass Spectrometry to Cardiovascular Biomarker
Discovery in SLE
CARDIOVASCULAR SLE
Biomarker or Mechanistic
MALDIBoth
Haptoglobin (Hp)
• Higher plasma Hpα2 seen in SLE vs.
TOF-TOF
α2 [112]
controls
and
ESI- • Supporting research has implicated Hpα2
MS/MS
isoforms in cardiac complications
[113,114]
MALDIBoth
Ro52 [110]
• Antibody protected sites found with SLE
TOF-TOF
sera in 200-239 amino acid portion of the
Ro52 protein
LC-MS/MS • Autoantibodies identified against Annexin Both
Annexin A6 [96]
A6
• Activation of Annexin A6 via
autoantibody resulting in impaired heart
function

SLE, Systemic Lupus Erythematosus; MALDI-TOF, Matrix Associated Laser
Desorption/Ionization-Time of Flight; ESI, Electrospray Ionization; Ro52 is also known
as tripartite motif protein 21 (TRIM21).
Korte et al. 2012.
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block and suggested potential mechanisms for the development of the condition
[115,116].
Haptoglobin α2 polypeptide chain differences have been noted between SLE and
non-SLE populations via MALDI-TOF-MS [112]. Patients expressing the haptoglobin
α2 isoform have been shown to have shorter survival times after coronary artery bypass
graft [113] and more severe complications after myocardial infarction [114], possibly due
to decreased ability to reduce oxidative stress.

The association of haptoglobin α2

peptides with SLE flare may offer insight into the cardiac complications seen in SLE and
higher levels of haptoglobin α2 have been reported in SLE patients vs. controls [112].
To identify target autoantigens and explore the pathogenesis of dilated
cardiomyopathy, Seko et al. [96] applied a 2-DE separation approach to plasma
membrane proteins isolated from rat cardiac myocyte cultures. The protein blot was then
probed with serum of healthy controls as well as a 17 year-old patient with an unusual
presentation of delayed cardiomyopathy subsequent to neonatal lupus erythematosus.
While the control showed no significant reactivity, many immune-reactive spots appeared
on the sample probed with SLE serum which were excised and analyzed on a LC-MS/MS
system. The analysis identified 2 high-probability proteins: annexin A6, known for
calcium signaling and membrane trafficking, and vimentin, known for maintenance of
cellular structure (Table 1).
The authors downplayed the likelihood of vimentin playing a role in the
pathogenesis of myocardial contractile dysfunction. However, mice with overexpressed
Annexin A6 had decreased contraction and relaxation of cardiac myocytes as well as
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dilated cardiomyopathy [117], suggesting that if autoantibodies to annexin A6 stimulate
its function, then the result would be suppression of myocardial activity.

3.3 – Immune cell involvement in systemic lupus erythematosus
SLE is, at its core, a disease of the immune system, so a deeper understanding of
immune cell function in both normal and diseased states is critical for a comprehensive
understanding of SLE. Complementary studies by Dai [118] and Wang [109] show the
evolution of a mass spectrometry-based interpretation of peripheral blood mononuclear
cells (PBMCs) in SLE. Dai et al. published their work in 2008 in which they compared
the relative changes in the proteome of PBMCs of both healthy controls and SLE
patients. They employed the conventional approach of 2-DE and silver stain followed by
MALDI-TOF/TOF to identify protein spots expressed at different levels. A total of 20
spots differed significantly between the SLE and control group with 11 being upregulated
and 9 downregulated. The findings of the study are summarized in Table 2. Briefly,
Immunoglobulin J chain, an early differentiation marker in B cells, was upregulated, as
was calprotectin L1, a protein released by granulocytes and monocytes during activation.
Interestingly, calprotectin L1 levels were associated with the severity of disease and at
the same time were linked significantly to anti-dsDNA antibodies.

Glutathione S-

transferase was downregulated in SLE, which would reduce the cell’s ability to degrade
reactive oxygen species, which may contribute to inflammation and tissue damage.
Wang et al. [109] followed Dai two years later with an expanded study which
employed the use of isobaric Tagging for Relative and Absolute protein Quantification
(iTRAQ) as a means of studying PBMC proteome changes. The iTRAQ method was
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Table 2 - Contributions of Mass Spectrometry to Immunological Biomarker
Discovery in SLE
IMMUNE CELL INVOLVEMENT IN SLE
Biomarker or Mechanistic
MALDIBoth
Immunoglobulin J
• Upregulated in SLE 2.46 fold
TOF
[118]
• Early differentiation marker for B-cells
MALDIBoth
Calprotectin
• Upregulated in SLE 2.02 fold
TOF
L1[118]
• Known marker of disease activity in RA
• Released from granulocytes and
monocytes during their activation
• Significantly tied to SLEDAI and higher
levels of anti-dsDNA antibodies and
SLE-arthritis
• May also inhibit Ig production
MALDIBoth
Glutathione S• Downregulated in SLE 0.15 fold
TOF
and
Transferase
(p=0.001) in one study and vs. diseased
iTRAQ 2D
[109,118]
and healthy controls
LC-MS/MS • Lower GST results in higher ROS levels
and increased oxidative stress
MALDIBiomarker
Apolipoprotein A• Upregulated in SLE 2.67 fold (p=0.010)
IV precursor [118] TOF
• Similar results seen in RA [119] and
Alzheimer’s Disease [120]
Both
Zinc finger protein MALDI• Upregulated in SLE 2.24 fold (p=0.041)
subfamily 1A [118] TOF
Zinc finger protein iTRAQ 2D • Upregulated in active SLE vs. stable SLE Both
– Isoform 2 protein LC-MS/MS
(2.7160), RA (2.3824) and Healthy
549 [109]
Controls (3.1042)
iTRAQ 2D • Upregulated in active SLE vs. stable SLE Both
Resistin [109]
LC-MS/MS
(3.6784) and Healthy Controls (2.2652)
• Verifies Previous Findings
iTRAQ 2D • Upregulated in active SLE vs. stable SLE Both
S100-P [109]
LC-MS/MS
(2.9641), and Healthy Controls (2.6475)
iTRAQ 2D • Upregulated in active SLE vs. stable SLE Both
S100-A12 [109]
LC-MS/MS
(2.3374), RA (2.0595)
iTRAQ
2D
Brain Acid Soluble
• Upregulated in active SLE vs. stable SLE Both
LC-MS/MS
Protein 1 [109]
(2.1139), Healthy Controls (2.6622)
iTRAQ 2D • Downregulated in stable SLE (0.4663)
Both
Ras-related C3
LC-MS/MS
Botulism Toxin
vs. diseased controls
Substrate 2 [109]

SLE, Systemic Lupus Erythematosus; SLEDAI, SLE Disease Activity Index; Ig,
Immunoglobulin; GST, Glutathione S-Transferase; LN, Lupus Nephritis; LC-MS/MS,
Liquid Chromatography Tandem Mass Spectrometry; MALDI-TOF, Matrix Associated
Laser Desorption/Ionization-Time of Flight; ESI, Electrospray Ionization
Korte et al. 2012.
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used with LC-MS/MS to allow multiplexing of samples (up to 8 per run), which not only
saves time, but also reduces technical variability. Using 6 samples each for active SLE,
inactive SLE, rheumatoid arthritis (RA) as a diseased control and healthy patient samples,
452 proteins with a variety of cellular locations and biological functions were identified
and quantified. Of these, 126 were either upregulated or downregulated across all the
groups. When compared to the 2008 data, this study showed a similar downregulation of
glutathione S-transferase and upregulation of zinc finger proteins with similar fold
changes in both experiments, but also identified several other known SLE regulators and
novel functional candidates.

In total, 17 proteins were upregulated and 13 were

downregulated in active vs. stable SLE. The author’s choices for future study are listed
in Table 1. Known SLE and inflammatory proteins were identified, such as resistin and
calcium-binding family of S100 proteins. Additionally, several novel candidate proteins
were identified, such as brain acid soluble protein 1 and ras-related C3 botulism toxin
substrate 2, which have roles in apoptotic mechanisms in other diseases [121,122], but
this was their first link to SLE disease activity.

3.4 – Lupus nephritis

Lupus Nephritis (LN) must be considered in a discussion on the use of proteomic
methods in lupus, because LN is one of the most common and most severe complications
that can arise from SLE (~50%), leading to significant morbidity and mortality [1]. As
with other renal disorders, a major diagnostic source for LN is urine. The advantage of
using urine as a screening method for presence or severity of disease is the non-invasive
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nature of sample collection. Urine studies also allow long-term observation of patients,
allowing tracking of changes in the urine proteome associated with changing disease
states. SLE and LN biomarkers have been a topic of discussion dating back to the 1960’s
and continue to be of interest today [111,123–125]. Recent proteomic studies have
provided insight into novel urinary biomarkers for LN and are summarized in Table 3.
Oates et al. [126] built on the ideas of urine protein quantification using 2-DE to
train an artificial neural network capable of identifying potentially significant changes to
urine proteomes immediately before validation by renal biopsy. Briefly, 200 μg protein
was collected from 20 different patients with SLE at the time of biopsy. The recovered
protein was denatured and separated using 2-DE. A total of 213 protein spots across the
20 patient gels were used to calculate protein abundance and an artificial neural network
was trained to identify the class of LN based on the protein abundance profile. The
resulting neural network was able to successfully identify >86% of all positives and
>92% of all negatives, with the exception of class V, where each false positive was
present in a sample also positive for Class III or IV LN, which were correctly identified.
The group then identified the most critical spots for determining sensitivity and subjected
each to MALDI-TOF-MS, which identified 6 proteins: α-1 acid glycoprotein, α1
microglobulin (2 spots), zinc α-2 glycoprotein (2 spots), and IgG κ light chain (Table 3).
Early work successfully identified proteomic profiles of renal flare in SLE
through the use of SELDI-TOF to identify protein signatures without the need to
positively identify proteins. This allowed the identification of novel biomarkers, but the
protein identification limitation of the SELDI-TOF technique prevented mechanistic
inference and predictions [127]. Zhang et al. [128] provided both diagnostic and
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Table 3 – Contributions of Mass Spectrometry to Biomarker Discovery in Lupus
Nephritis
LUPUS NEPHRITIS
2-DE then
α-1 acid
glycoprotein [126] MALDITOF
2-DE then
α1 microglobulin
MALDI[126]
TOF
2-DE then
zinc α-2
glycoprotein [126] MALDITOF
2-DE then
IgG κ light chain
MALDI[126]
TOF
SELDIα-1 Antitrypsin
TOF then
[128]
LCMS/MS
SELDIAlbumin [128]
TOF then
LCMS/MS
SELDIHepcidin-20
TOF then
[128,129]
LCMS/MS
LCAldolase A [111]
MS/MS

Biomarker or Mechanistic
Biomarker
• Diagnosis and Class Identification of
LN
• Diagnosis and Class Identification of
LN

Biomarker

• Diagnosis and Class Identification of
LN

Biomarker

• Diagnosis and Class Identification of
LN

Biomarker

• Upregulated in the urine at baseline and
2 months pre-flare until 4 months postflare

Biomarker

• Upregulated in the urine at baseline vs.
flare

Biomarker

• Upregulated in the urine 4 months preflare

Biomarker

• Autoantibodies more common in LN
patients than SLE without LN
• Antibody specific to 94-183 aa epitope
may be LN-specific biomarker

Biomarker

SLE, Systemic Lupus Erythematosus; LN, Lupus Nephritis; LC-MS/MS, Liquid
Chromatography Tandem Mass Spectrometry; MALDI-TOF, Matrix Associated Laser
Desorption/Ionization-Time of Flight; ESI, Electrospray Ionization; SELDI, Surface
Enhanced Laser Desorption/Ionization
Korte et al. 2012.
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mechanistic understanding of LN using longitudinal urine proteomics to assess the
changes in the urine proteome before, during and after SLE renal flare by combining
SLEDI-TOF with LC-MS/MS sequencing for protein identification. Using a sample set
of 145 urine specimens from SLE Class III, IV and V patients, they identified 27 low
molecular weight proteins that showed significantly different levels of expression before,
during or after SLE flare. While no single peptide was present in all the flare or non-flare
samples, combinations of two peptides were found that successfully differentiated 100%
of the remission and pre-flare samples from flare and post-flare samples. LC-MS/MS
analysis identified multiple isoforms of α-1 Antitrypsin, albumin, and hepcidin as
proteins of interest (Table 3). Interestingly, Hepcidin-20 levels were only altered preflare, which means Hepcidin-20 may be a useful indicator of impending flare, allowing
modulation of clinical management to reduce severity and duration of the flare. A follow
up study two years later supported this idea and further presented IL-6 and INFαdependent upregulation of Hepcidin transcription as a possible mechanism of Hepcidin
increase in LN [129].
A study using LC-MS/MS to characterize immune-reactive bands from 2-DE
separated endothelial cell lysate with sera of SLE patients, other autoimmune conditions
and healthy controls identified the glycolytic enzyme aldolase A as a candidate target
antigen [111] (Table 3). Moreover, this was found to be more common for LN patients
than in SLE without LN (43.4% with LN vs. 11.1% without LN). However, reactivity to
aldolase A was not appropriately significant between LN and other inflammatory disease
controls such as RA and polymyositis to be used as a stand-alone biomarker for LN. The
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authors did however note specificity of LN patient anti-sera to the 94-183 aa region of
aldolase A over other autoimmune conditions.
Suzuki et al. used a combination of SELDI-TOF [130] and MALDI-TOF [131]
for evaluation of the urine proteome in pediatric LN (Table 4).

Four potentially

significant biomarkers were identified including transferrin (Tf), ceruloplasmin (Cp), α1acid-glycoprotein (AGP), and lipocalin-type prostaglandin-D synthetase (L-PGDS), each
with great significance (p<0.005, Table 3). Significant increases of Tf, L-PGDS, and
AGP were seen as early as 3 months before clinical diagnosis or worsening of LN. Both
Tf and AGP were also seen in adult forms of the disease [132], while L-PGDS is novel to
pediatric LN diagnosis. Cp has been implicated in global SLE, but was not found to be
an effective metric for defining the course of LN in pediatric patients.

3.5 – Neuropsychiatric systemic lupus erythematosus

Neuropsychiatric SLE (NPSLE) is a potentially severe complication that varies in
its prevalence between 9.5%-95% based on the literature cited and the diagnostic criteria
[133]. Findings suggest that NPSLE can be present in a mild form in as many as 95% of
SLE patients [134], making it more common but typically less severe than renal or
cardiovascular complications.

Mood disorders and cognitive disorders are common

symptoms and can be particularly challenging to diagnose in pediatric and adolescent
patients due to the rapid emotional and physical changes that occur at those ages. While
acquisition of cerebral spinal fluid (CSF) is invasive, it has become routine in the
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Table 4 - Contributions of Mass Spectrometry to Biomarker Discovery within
Pediatric Populations of Lupus Nephritis Patients
PEDIATRIC LUPUS NEPHRITIS
Biomarker or Mechanistic
SELDIBiomarker
Transferrin (Tf)
• Upregulated in worsening disease and
TOF then
[130,131]
flares in pediatric patients
MALDI• Plasma Tf related to global SLE
TOF
activity
MS/MS
• Urine Tf was related to LN disease
activity
SELDIBiomarker
Ceruloplasmin
• Upregulated in pediatric SLE and LN,
TOF then
(Cp) [130,131]
but cannot specify between different
MALDIclasses of LN activity
TOF
MS/MS
SELDIα1-acid• AGP from plasma is for global pediatric Biomarker
TOF then
glycoprotein
SLE
MALDI(AGP) [130,131]
• AGP from urine is specific to pediatric
TOF
LN
MS/MS
• Useful to anticipate renal flares
SELDIBiomarker
Lipocalin
• Type prostaglandin-D synthetase (LTOF then
[130,131]
PGDS) – role in chemotherapy induced
MALDIrenal damage (plasma and urine)
TOF
• Novel to LN
MS/MS
LCBiomarker
Aldolase A [111]
• Anti-aldolase A antibodies have been
MS/MS
found to be more common in SLE with
LN than SLE without LN (43.4% to
11.1%)
• Possible specificity for other
autoimmune conditions via presence of
antibodies to the 94-183 aa epitope

SLE, Systemic Lupus Erythematosus; LN, Lupus Nephritis; Tf, Tranferrin; AGP, α1acid-glycoprotein (AGP); LC-MS/MS, Liquid Chromatography Tandem Mass
Spectrometry; MALDI-TOF, Matrix Associated Laser Desorption/Ionization-Time of
Flight;

ESI,

Electrospray

Ionization;

Desorption/Ionization
Korte et al. 2012.
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SELDI,

Surface

Enhanced

Laser

diagnosis of many neurological diseases and therefore in addition to serum, CSF is a
useful medium for proteomic study of NPSLE. NPSLE research has focused on both
biomarker identification for its diagnostic value as well as autoantigen identification for
improved mechanistic understanding of the disease state and potential therapeutic
development (Table 5).
Lu et al. [94] found CSF and sera obtained from NPSLE patients to be reactive to
rat, mouse and monkey brain homogenate when separated by 2-DE. MALDI-TOF-TOF
was used to identify immune-reactive proteins. A total of 275 serum samples and 177
CSF samples were included, giving a great deal of depth and statistical power to the
study. Briefly, four anti-ANA-positive serum samples, which did not react to Hep2 cells,
were used as pilot samples. Initial analysis of the reactive spots revealed an interaction in
3 of 4 samples with α-internexin (INA), a highly conserved protein between rodents and
humans (Table 5). Recombinant human INA was then used in a western blot to confirm
reactivity of sera as well as immunofluorescence with sera and anti-INA polyclonal
antibody (pAb). Both the sera and the pAb were found to react to cultured rat cortical
neurons and the reactivity of sera was reduced by incubation with recombinant INA.
These findings opened the door for analysis of the entire cohort of CSF and serum
samples. Using 2 standard deviations as a cutoff for positivity, 41.7% of the NPSLE
samples of CSF were found to be positive for anti-INA antibodies (as compared to 0% of
SLE with cerebral infarction, 7.1% of normal SLE controls, and 10% of other
neurological diseases). In total, the data showed reactivity in >40% of NPSLE patients in
a dose dependent manner toward INA. Longitudinal studies found that antibody levels
were inversely proportional to cognitive level and declined after initiation of therapy and
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Table 5 - Contributions of Mass Spectrometry to Biomarker Discovery in
Neuropsychiatric SLE
NEUROPSYCHIATRIC SLE
2-DE then
Intermediate
MALDIFilament αTOF
internexin (INA)
[94]
α-tubulin [136]

β-tubulin [136]

Crystalline αB [95]
Esterase D [95]
APEX nuclease 1
[95]

60 kDa Heat Shock
Protein [135]

Anti-Rab guanosine
diphosphate
dissociation
inhibitor α (antiαGDI) [123]

Biomarker or Mechanistic
Both
• Reactive antibodies found in NPSLE
patient sera in 41.7% of patients (7.1% of
SLE, 0% healthy controls and 10% of
other neurological diseases)
• Results verified [135]
MALDIBoth
• Autoantibodies were found in 36% of
TOF then
NPSLE, (vs. 4% of SLE and 0% HC)
Q-TOF
• More frequently seen in severe (50%)
than mild (20%) NPSLE
• Confirmed by LC-MS/MS [95]
MALDI• Previously identified in other autoimmune Both
TOF then
conditions such as multiple sclerosis and
Q-TOF
Guillain-Barre
• Confirmed by LC-MS/MS [95]
LC-MS/MS • Novel sera and CSF autoantigen for
Both
active NPSLE
LC-MS/MS • Novel sera and CSF autoantigen for
Both
active NPSLE
LC-MS/MS • Novel sera and CSF autoantigen for
Both
active NPSLE
• More reactive in SLE than other
autoimmune conditions
LC-MS/MS • Autoantibodies directed against cerebral
Both
lysates found in sera of NPSLE patients
with WMH
• Known to cause endothelial cell apoptosis
and coronary artery disease
• Results verified [124]
LC-MS/MS • Found in 80% of NPSLE patient sera with Both
psychosis (vs. 5.3% of NPSLE without
psychosis and none of the CNS control
samples)

NPSLE, Neuropsychiatric SLE; CSF, Cerebral Spinal Fluid; WMH, White Matter
Hypertrophies [on MRI]; CNS, Central Nervous System; LC-MS/MS, Liquid
Chromatography Tandem Mass Spectrometry; MALDI-TOF, Matrix Associated Laser
Desorption/Ionization-Time of Flight
Korte et al. 2012.
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clinical remission.

Furthermore, mice immunized with INA plus LPS developed

cognitive impairments similar to NPSLE and exhibited hippocampal and cortical neuron
apoptosis, suggesting that the presence of anti-INA antibodies in the serum of patients
was pathogenic.
Ndhlovu et al. [136] identified α- and β-tubulin as target autoantigens for NPSLE
using patient sera to probe isolated mitochondria from bovine brain followed by MALDITOF analysis. Autoantibodies to β-tubulin have been identified in other CNS targeting
autoimmune diseases such as Guillain-Barre syndrome, Multiple Sclerosis, and
Sydenham’s chorea, but targeting of α-tubulin is potentially specific to NPSLE. αtubulin autoantibodies were present in 36% of NPSLE patient sera, only 4% of SLE
patients without neurological symptoms and none of the MS, epileptic or healthy control
samples (Table 5). Possibly due to the small size of the NPSLE population in the study
(n=37), no correlation was seen between specific symptoms of NPSLE and the presence
of α-tubulin autoantibodies in sera. Larger patient population studies are needed to
further explore the involvement of anti-α-tubulin antibodies in NPSLE.
LC-MS/MS incorporates a direct front-end separation of complex samples to
greatly increase the sensitivity of the procedure for low abundance protein detection. LCMS/MS may be superior to MALDI-based techniques when dealing with complex
samples. Katsumata et al. found this to be true while attempting to uncover novel serum
autoantibodies for SLE, in particular those involved in CNS syndromes [95]. Whole
protein extracts from human neuroblastoma and glioblastoma cell lines were separated
using 2-DE and reacted to patient sera. It was determined that MALDI-TOF sensitivity
was too low for effective protein identification in this case. To address this concern, anti-
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sera from SLE patients with and without CNS syndromes was bound to Protein GSepharose beads and incubated with the same cell line extracts. Proteins pulled down
with the Sepharose beads were analyzed with a LC-MS/MS method using a Q-TOF
instrument. Most of the 154 proteins identified by the LC-MS/MS approach were not
identified in the 2-DE/MALDI-TOF analysis and 50 were found in the CNS group but
not the non-CNS group.

After exclusion of previously described autoantigens, 11

recombinant candidates showed reactivity against pooled serum of 28 patients with active
CNS SLE by western blot analysis (5 of which were only detected by LC-MS/MS).
These 11 candidates were then probed with sera of 106 SLE patients (42 with active CNS
syndromes) as well as 100 healthy controls, resulting in a list of 5 confirmed
autoantigens, 3 of which were novel (crystalline αB, esterase D and APEX nuclease 1,
Table 1). When compared to other diseased sera (RA, SSc, SS, and MS), levels of anticrystalline αB was not found to be significantly different. Anti-APEX nuclease 1 and
esterase D, on the other hand, had significantly higher levels in SLE than in these disease
controls and between CNS and non-CNS SLE sera. APEX nuclease 1 is the major
apurinic/apyrimidinic endonuclease in human cells and is found to be upregulated in
tissues under oxidative stress and has a significant effect on apoptotic regulation in
certain tissues [137]. The effects of esterase D are less well known.
In a similar study, Kimura et al. used a combination 2-DE and LC-MS/MS with
an ESI-LCQ instrument to obtain higher sensitivity for low abundance proteins [135].
Patient sera from a NPSLE patient with white matter hyperintensities (WMH) on T2weighted MRI scan was reacted to a 2-DE rat cerebral lysate blot. In total, 9 reactive
spots were seen and 5 were analyzed by LC-MS/MS. The 2 spots of greatest intensity
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corresponded to 60 kDa Heat Shock Protein (Hsp60) [135], which functions to refold
proteins that are misfolded and/or facilitate degradation of proteins that cannot be
recovered [138]. Enhanced expression of Hsp60 can induce endothelial cell apoptosis
and Hsp60 expression on the surface of endothelial cells have been reported to be directly
related to coronary artery disease [139], opening the possibility of a similar relationship
in the cerebral vasculature. In a follow-up study of 180 patients with neurological
diseases (including 15 with SLE) and 23 healthy controls, Kimura et al. showed that the
titer levels of anti-Hsp60 were directly correlated to severity of WMH in the brain,
suggesting the presence of anti-Hsp60 as both a diagnostic tool as well as a mechanistic
agent in the development of NPSLE [124]. Although the authors chose to focus on
Hsp60, the study also found SLE specific antibodies to α-internexin, β-actin, and glial
fibrillary acidic protein (Table 5).
Another study using LC-MS/MS also suggested a relationship between NPSLE
exhibiting psychosis with anti-Rab GDI-α [123]. LC-MS/MS and WB analysis of sera
found that 4 of 5 patients with NPSLE with psychosis (80%) expressed anti-Rab GDI-α
(Table 5), while 1 of 13 patients with NPSLE and none with psychosis (5.3%) expressed
the autoantibody, along with no expression in patients with multiple sclerosis (n=12),
infectious meningoencephalitis (n=13), polyneuropathy (n=10), psychotic syndromes
(n=10), or healthy controls (n=12).

3.6 – Other uses for proteomics in the study of SLE
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Aside from assessing differences in disease states, pharmacologic reactions can be
measured using proteomic techniques. Kao et al. [140] used a 2-DE and MALDI-TOF to
investigate the changes to apoptotic-prone macrophages (APM) from lupus-prone
NZB/W-F1 mice before and after treatment with cystamine, a known inhibitor of
transglutaminase 2 (TG2) activities. A number of the findings indicated that cystamine
has anti-apoptotic affect in the APMs and suggests possible mechanism of this activity.
Protein expression and enzyme activity of Caspase 3 were downregulated and antiapoptotic proteins APIP, PEBP4, and Bcl-2 were upregulated. ERK 1/2 showed reduced
phosphorylation after treatment in APMs, which also would result in survival of APMs
and fewer apoptotic bodies to serve as potential targets for autoantibody production.
Previous studies have shown that ERK 1/2 phosphorylation is increased with cystamine
treatment in endothelial cells [141] and neuronal tissue [142], therefore the findings of
decreased phosphorylation in APM may help further explain the development of SLE in
specific tissues and lead to a more complete model of pathogenesis.
Mass spectrometry can also be useful as a supplemental technique of a study. In
work primarily focused on genetics, D’souza et al. [143] utilized MALDI-TOF-MS to
support the hypothesis that catalase polymorphisms affect the risk and severity of SLE.
Oxidative processes resulted in the 4-hydroxy 2-nonenol (4-HNE) adducts on membrane
catalase of red blood cells (RBCs). MALDI-TOF was of great use in this situation
because it allowed the positive identification of catalase from RBC membranes (an
uncommon location) while migrating at a higher molecular weight, possibly due to 4HNE adducts. Ye et al. [144] expanded on previous microarray data by selecting a gene
that is upregulated in SLE (interferon-induced with tetratricopeptide repeats 1 - IFIT1),
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creating a IFIT1 fusion protein with GST, and then using bead immobilized GST-IFIT1
as bait to capture interacting proteins in white blood cell lysate. MALDI-TOF was
performed on the proteins pulled down in the procedure and found Rho/Rac guanine
nucleotide exchange factor to be a potential target for IFIT1 interaction in SLE. Follow
up studies have supported the role of the interferon pathway in SLE and other
autoimmune diseases [145–147].

3.7 – Characterization of the Secretome of Cultured Cells

Cell culture provides an opportunity to isolate a cell type from the organism to
analyze its function in a controlled setting. It is not possible to replicate all biological
events which would take place in a mammalian system, but experimental models utilizing
cell culture for initial discovery can be useful to identify low abundant targets or factors
from specific cell populations which would otherwise be masked in a typical body fluid
sample.
The global hypothesis of this dissertation succinctly states that podocyte activity
can promote the development of GN, and that ABIN1 is important to prevent
inflammation in local tissues. This is not, however, to say that cells of the immune
system are not involved.

NF-κB-mediated signaling events in mesangial cells and

podocytes are known to promote synthesis and secretion of pro-inflammatory cytokines
and chemokines which recruit neutrophils, macrophages and other immune cells to
tissue[148–152]. Normal immune cell functions in these tissues include clearing of
infectious material and cellular debris, while inappropriate or excessive recruitment by
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podocytes and mesangial cells to otherwise healthy tissue can lead to inflammatory
damage. The renal secretome is an incompletely characterized collection of factors
released by the cells of the kidney[152]. We characterized the normal secretome of
podocytes and simultaneously investigated ABIN1-related changes to the secretome
which may attract excessive numbers of immune cells to the kidney, resulting in local
conditions which may promote LN [148–151,153–158]. This was accomplished through
a relatively unbiased analysis of the secretome of each cell type under varying conditions
with two-dimensional liquid-chromatography tandem mass spectrometry (2D-LCMS/MS).
Method development focused on establishing a sample of appropriate purity but
with sufficient chemical properties suitable for LC-MS/MS analysis. Three factors were
of great importance:

(1) the chosen stimulant, TNF-α, could mask low abundant

cytokines via ion suppression and additionally would hinder measurement of TNF-α
produced by the podocyte, (2) the proteomic makeup of the cell culture media would
have to be sufficient for LC-MS/MS analysis, and (3) the media had to be sufficient for
proper podocyte cell functions and could not induce unnecessary stress on the cells which
would undoubtedly affect their inflammatory profile. Podocyte cell culture media is
comprised of 10% FBS, which contains a host of protein “contaminants”, and phenol red
can confound LC-MS/MS analysis and should be avoided. In addition to the chemical
components of the media, the timing of stimulation and sample collection need to be
optimized for each cell type used and for each stimulant.

Following a number of

preliminary experiments, I arrived at a protocol which accomplished all of these
preconditions.

Podocytes were stimulated in 10cm dishes for 6 hours in 10mL serum-
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free media, followed by 3 washes in 10mL warm Krebs buffer, and a 6 hour collection in
warmed Krebs buffer. Figure 8 outlines the kinetic properties of cultured podocytes
stimulated from 0-18 hours with TNF-α and shows that a 6 hour stimulation was
sufficient to induce production of 3 important proinflammatory cytokines, MCP-1, GMCSF, and IL-8. In addition, I also was able to remove the TNF-α used for stimulation to
below detectible levels of our ELISA assay (<<2 pg/mL). This was important for both
LC-MS/MS analysis as well as downstream characterization of these samples using
biological methods (see Chapter V).
Once optimal timing and media components were achieved, sample analysis had
to be addressed. Most cytokines are small proteins and we have found that sample purity
is increased through a 10 minute centrifugation in an Amicon Ultra-30kDa Centrifugal
Filter Unit (Millipore, Billerica, MA) to remove proteins larger than 30 kDa, followed by
standard trypsin digest and LC-MS/MS sample preparation as described in the materials
and methods. Figure 9 shows protein identifications without this cutoff and includes a
number or large, high abundant proteins such as fibronectin and actin. Figure 10 outlines
proteins identified after the 30 kDa cutoff was applied before trypsin digestion. A
number of cytokines expected to play a role in GN are shown to be upregulated in the
podocyte secretome, including IL-6, MCP-1 (CCL2) and the cell adhesion molecules
VCAM1 and ICAM1. The benefit of mass spectrometry-based approaches is the ability
to identify novel proteins from a given sample, and a number of promising candidates for
future study were identified such as transgelin and TIMP1 which have a role in matrix
remodeling and perlecan, filamin, cofilin and moesin. Of note, a side project involving

67

Figure 8 – Kinetics of Cytokine Secretion by Podocytes in Response to TNF-α
Stimulation
Podocytes were produced and treated as described in the Materials and Methods.
TNF-α stimulation (100ng/mL) at time points from 0-18 hours was used to
determine the kinetics of cytokine production using ELISA to measure cytokine in
pg/mL. It was found that from 0-6 hours of TNF-α stimulation, TNF-α response
resulted in high levels of cytokine production. Further, the wash step following the
18 hour time point resulted in all analytes dropping below their detectible level for
their respective assays, and this included TNF-α which was the stimulant.
Erik Korte. Unpublished.
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Figure 9 - Identification of Total Protein Secreted from Cultured Podocytes
Cell culture supernatant was prepared from cultured podocytes as described,
digested and prepared for LC-MS/MS analysis.

Identified peptides were

predominantly highly abundant matrix proteins and large cytosolic proteins, rather
than the typically small (<30kDa) cytokines and chemokines.
identified 932 proteins and 35,075 unique spectra.
Erik Korte. Unpublished.
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This analysis

Symbol
VIM
IL6
TAGLN
HSPG2
SCRN1
GREM1
LGALS3BP
SERPINH1
CNN3
LUM
ANXA3
TMSB4X
SERPINA1
MSN
STIP1
FLNC
CFL1
TPT1
CCL2
COL4A1
ILF3
BMP1
C1S
NPC2
VCAM1
TIMP1

Unstim
TNF-α Stimulated
WT
D472N
WT
D472N
120.960
65.491 101.780
68.065
5.125
6.742
4.425
10.256
5.125
12.520
6.638
16.783
18.451
52.008
17.701
61.538
1.025
2.889
1.106
4.662
3.075
9.631
4.425
8.392
1.025
10.594
1.106
8.392
5.125
9.631
5.532
9.324
6.150
10.594
4.425
10.256
5.125
9.631
4.425
10.256
4.100
7.705
2.213
10.256
13.326
22.151
17.701
11.189
18.451
29.856
21.020
38.228
29.726
41.414
42.040
50.350
13.326
10.594
12.169
7.459
12.301
9.631
8.850
7.459
37.927
15.410
29.870
13.986
2.050
6.742
4.425
4.662
4.100
3.852
5.532
4.662
1.025
8.668
1.106
4.662
4.100
5.779
6.638
5.594
1.025
4.816
1.106
5.594
2.050
5.779
1.106
5.594
3.075
2.889
2.213
5.594
0.000
0.000
1.106
5.594
5.125
7.705
5.532
7.459

Figure 10 – Identification of Proteins Secreted by Podocytes Following 30 kDa
Size-Selective Filtration
Most cytokines and chemokines are small peptides of less than 30 kDa. Thus, to
prevent contamination and ion suppression from highly abundant proteins, an Amicon
Ultra-30kDa Centrifugal Filter Unit from Millipore was used to remove proteins larger
than 30 kDa before tryptic digestion. The heatmap represents the Protein Abundance
Factor (PAF) which provides a quantitative value for each identified peptide while
taking into account the total protein’s size, with the understanding that larger proteins
will produce more digested peptide fragments and thus will artificially result in higher
numbers of peptide identification.
Erik Korte. Unpublished.
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moesin has suggested it may be directly involved in the pathogenesis of GN as an
autoantigen for a small population of patients with membranous glomerulonephropathy.

3.8 – Conclusions

Many of the studies presented in this review were aimed at using proteomic applications
to define events in specific SLE complications, but it is our view some of these
discoveries could also provide insight into other areas of SLE or that approaches applied
to similar diseases could be modified for use in SLE. Recent studies have shown the use
of MALDI-TOF techniques for synovial fluid analysis in autoimmune arthritis [159],
which could be used to assess changes in SLE arthritis. Kimura et al. [135] identified a
60 kDa Heat Shock Protein as an autoantigen in NPSLE, a protein with known ties to
coronary artery disease and endothelial cell apoptosis [139,160,161] which may play a
role in the development of cardiovascular SLE. Several studies have shown the benefits
of proteomics using bronchoalveolar lavage fluid (BALF) as a sample for the study of
sarcoidosis [162], systemic sclerosis [163,164], and other pulmonary diseases [165,166].
The use of BALF for the study and diagnosis of pulmonary complications in SLE would
be less invasive and safer than biopsy. Tamburro et al. [167] recently published a
proteomic review of the vitreous humor of the eye. Contrasting these findings to the
proteome of SLE patient’s vitreous humor could shed more light on the pathogenesis of
retinopathy in SLE. Dai et al. [118] found Immunoglobulin J to be upregulated in
peripheral blood mononuclear cells. Other mass spectrometry-based techniques could be
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used such as multiple reaction monitoring (MRM) and Selected Reaction Monitoring
(SRM) LC-MS/MS, which allows focused study on only m/z ratios of interest, reducing
sample processing time and greatly increasing throughput. After the initial biomarker
discovery stages, MRM/SRM has been used as a tool in biomarker validation in blood
[168] and synovial fluid, specifically in RA patients [169]. Additionally, the speed and
potential for multiplexing means MRM/SRM could have clinical utility in patient
diagnosis, prognosis, and monitoring [170]. We used a LC-MS/MS approach to identify
the M-type phospholipase A2 receptor (PLA2R) as the target antigen in idiopathic
membranous nephropathy (iMN) [5]. Antibodies recognizing the PLA2R were present in
70% to 80% of iMN patients. However, they are not present in any patients with
membranous lupus nephritis (MLN), which develops in up to 40% of patients with LN
[171]. This suggests that there are unique autoantibodies directed against specific kidney
proteins other than the PLA2R in MLN. Therefore, proteomic studies could be designed
to identify such target antigens as well as specific epitopes important in MLN.
Even with the strides we have made in the understanding of SLE, it is still a
debilitating condition effecting hundreds of thousands of patients every year. While
treatments are available, they bring with them significant side effects and frequent failure
rates. Recent advances in mass spectrometry technology have allowed an even more
thorough analysis of complex samples to better understand the significance of minute
changes in the pathogenesis of SLE, while accommodating large sample sizes through
multiplexing and high throughput methods. The method I outline here can serve as a
starting point for optimization of LC-MS/MS analysis for the secretomes of many diverse
cell populations and may have applications in primary body fluid as well. The options
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researchers or clinicians have in mass spectrometry techniques are rapidly expanding and
have the ability to be tailored to a specific study. It is my hope that the characterization
of the potential applications of mass spectrometry will provide a greater knowledge of the
diverse uses of mass spectrometry and other proteomic technologies in the study of SLE,
GN and other conditions. While a proteomic understanding of disease is by no means a
panacea, it offers the potential to help advance our knowledge and understanding of SLE
to a point that the disease could be less of a burden for those afflicted.
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CHAPTER IV

ABIN1 DYSFUNCTION AS A GENETIC BASIS FOR LUPUS NEPHRITIS

4.1 – Introduction

As stated previously, SLE is a multi-system autoimmune disease that is
characterized by an abnormal immune response leading to autoantibody production,
immune complex formation, T cell activation, and inflammatory cytokine release [8].
Multiple factors contribute to SLE and LN is a frequently associated condition which is
devastating to the patient [8,10]. The pathogenesis of LN is variable among different
ethnic groups showing a genetic link, but current therapies are ineffective in half the
population and carry major side effects [4,14].
Our lab has previously characterized SLE-like autoimmunity in a mouse model
expressing ABIN1[D485N] [53]. Due to the more than casual relationship between SLE
and LN, I asked if these mice could present a renal phenotype which would shed light on
the major glomerular events in the pathogenesis of LN. A major symptom of renal
dysfunction is protein loss into the urine from resulting from glomerular damage [16].
Urine albumin:creatinine ratios (UAC) present a method for analysis of spot urine by
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measure the serum protein albumin against the level of creatinine in the urine which is
freely filtered into the urine and not secreted to a great degree by tubule cells, and thus
provides an appropriate normalization factor for glomerular filtration compared to
reabsorption of water in the tubules [172].
Physiological changes in both mouse models and human disease include foot
process effacement and expansion of the mesangial matrix and will be described in this
spontaneous model of autoimmunity to further suggest a GN-like phenotype [17].
Complement component 3 (C3) plays a central role in the innate immune response and
inflammation, and low serum C3 is a diagnostic criteria for SLE [173]. Here I seek to
characterize the changes in this model of spontaneous autoimmunity as it pertains to
human disease, and begin to identify the molecular mechanisms responsible for the
pathogenesis of LN with the hope to define more specific diagnostic and therapeutic
targets.

4.2 – Results

Renal Pathophysiology of ABIN1[D485N] knock-in mice
We reported previously that ABIN1[D485N] mice develop antibody-mediated
glomerulonephritis [53]. The aim of this study was to provide a complete characterization
of the renal abnormalities in these mice. Table 6 presents the evaluation of the histologic
grading of glomerular changes in wild-type (WT) and ABIN1[D485N] mice at 3-4
months and 5-6 months of age. The scoring system used for histologic grading is
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Glomerular
WT 3-6mo
0 (0)
[D485N]
3- 0 (0)°
4mo
0.09 (0.09)°/°

Caster/Korte et al. 2013.

The numbers are derived using a scoring system described in Materials and Methods.
a, p-values for ABIN1[D485N] vs WT
b, p-values for ABIN1[D485N] 3-4 month vs 5-6 month
*p<0.05, **p<0.005, ***p<0.001, °Not Significant

Crescents
0 (0)
0 (0)°
0.09 (0.09)°/°

Interstitial
Interstitial
Tubular
Inflammation
Fibrosis
0 (0)
0 (0)
0 (0)
0 (0)°
0.55 (0.16)*
0.09 (0.09)°
0.64 (0.24)°/° 1.55 (0.25)***/* 0.82 (0.26)*/°

Endocapillary
Mesangial
Proliferation
Expansion
0 (0)
0 (0)
1.27 (0.27)**
1 (0.13)***
2.73
2.36

Mesangial
Proliferation
0 (0)
1.73 (0.19)***
1.82

Glomerular
Glomerular Size Proliferation
WT 3-6mo
0 (0)
0 (0)
[D485N]
3- 1.91 (0.16)***a 2 (0.19)***
4mo
2.73
2.82

TOTAL
Pathology
0 (0)
8.55 (0.88)***
15.64

Table 6 – Glomerular, interstitial and tubular pathology assessment in wild-type (WT) and ABIN1[D485N] kidneys.

described in Chapter 2. Glomerular size, mesangial and endocapillary proliferation, and
mesangial expansion in ABIN1[D485N] mice were all significantly increased by 3-4
months. By 5-6 months ABIN1[D485N] mice demonstrated a significantly progressive
increase in glomerular size, endocapillary proliferation, and mesangial expansion, when
compared to 3-4 month old ABIN[D485N] mice (Figure 11a). All mice at 3-4 months of
age demonstrated glomerular hypercellularity, with 50% showing severe (3+) changes.
Hypercellularity was focal in 2 mice and diffuse in 9. At 5-6 months all mice showed
diffuse hypercellularity and all but one were histologically graded as severe (3+). An
increase in mesangial matrix was seen in 8 of 11 mice at 3-4 months, but was only mildly
increased in 3 of those 8 mice. At 5-6 months, all but one mouse demonstrated a
moderate to severe increase in mesangial matrix. Crescents were only observed in 2 mice
at 5-6 month, and glomerular sclerosis was seen in 4 of those mice.
Table 6 and Figure 11b show that there was a significant amount of interstitial
inflammation in ABIN1[D485N] mice at 3-4 months of age, while little or no tubular
atrophy or interstitial fibrosis was observed. By 5-6 months, there was a significant
increase in interstitial inflammatory cell infiltration, tubular atrophy and interstitial
fibrosis (Figure 11b). Mild interstitial inflammation was seen in only 4 of 11 mice at 3-4
months. By 5-6 months, all mice had some degree of interstitial inflammation, which
was moderate or severe in 8 of 11 mice. Mild, patchy tubular atrophy was seen in less
than 50% of mice in each age group. A sparse amount of tubulointerstitial fibrosis (TIF)
was seen in 2 of 11 mice at 3-4 months and mild to moderate TIF was observed in 6 of 11
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Figure 11 – ABIN1[D485N] Mice Develop Severe Progressive GN
Glomerular, interstitial, and tubular pathology was assessed by evaluation of a complete
cross- section of an entire kidney in a blinded manner. Glomerular damage was assessed
by semiquantitative scoring of size, cellularity, mesangial matrix expansion, crescent
formation, and sclerosis on a 0 (normal), 1+ (mild abnormality), 2+ (moderate
abnormality), and 3+ (severe abnormality)

scale. The semiquantitative scoring of

interstitial inﬂammatory cell inﬁltration, interstitial ﬁbrosis, and tubular atrophy was
based on the percentage of interstitium area affected: 0, normal; 1+, <25% of interstitial
cross-section affected; 2+, 25%–50% of interstitium affected; 3+, >50% of interstitium
affected in a single cross-section of an entire kidney. An activity index was calculated as
the sum of individual scores for glomerular size, glomerular hyper- cellularity, cellular
crescents, mesangial expansion, and interstitial inﬂammation. We also determined
whether the lesions were focal (involving <50% of the glomeruli) or diffuse (involving
>50% of the glomeruli).
Caster/Korte et al. 2013.
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mice at 5-6 months. There were no differences in histologic injury between male and
female mice.
Figure 12 shows that the urine albumin to creatinine (UAC) ratio was
significantly elevated in 3-4 month old ABIN1[D485N] mice compared to WT. The urine
albumin excretion did not increase further in 5-6 month old ABIN[D485N] mice.
Surprisingly, serum C3 was found to be significantly higher in 3-4 month old
ABIN1[D485N] animals compared to WT mice, but C3 was markedly decreased in the 56 month old ABIN1[D485N] mice (Figure 13). Our previous study showed that
antinuclear antibodies were present by 3-4 months of age in ABIN1[D485N] mice [53].
The following figures include representative examples of the histology depicted in
Table 6 and Figure 11. Figure 14b shows a glomerulus from an ABIN1[D485N] mouse
at 4 months of age demonstrating mild mesangial and endocapillary hypercellularity with
little or no mesangial matrix expansion or interstitial inflammatory infiltrate, and Figure
14a shows a glomerulus from a WT mouse for comparison. Figure 14c shows a
glomerulus from a WT 6 month old mouse. Figure 14d, Figure 15, and Figure 16 show
the more severe glomerular changes seen in 5-6 month old ABIN[D485N] mice. Figure
14d shows a glomerulus with moderate mesangial and endocapillary cell proliferation
and a thickened capillary loop wall typical of “wire loops” (arrow). Figure 15 shows an
example of severe glomerular hypercellularity, marked mesangial matrix expansion, and
severe interstitial cell infiltration (arrow). Figure 16 shows a glomerulus with crescent
formation (arrow), glomerular sclerosis, and interstitial fibrosis.
Figure 17a shows a transmission electron micrograph (TEM) from a 6 month old
wild type mouse. Figure 17b shows a TEM from a 4 month old ABIN1[D485N] mouse
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Figure 12 – Urine Albumin to Creatinine is Elevated in ABIN1[D485N] Mice
Urine albumin-to-creatinine ratio of 3- to 4-month-old and 5- to 6-month-old
ABIN1[D485N] and WT mice (total n=82) show significant protein loss into the urine
by 3-4 months of age in ABIN1[D485N] mice compared to ABIN1 WT. Significance
was calculated using Mann-Whitney rank order analysis (* p<0.05 and ** p<0.001).
Caster/Korte et al. 2013.
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Figure 13 – Complement Component 3 Levels are Reduced in Late Disease
Reduced serum C3 levels are a clinical sign and diagnostic factor of SLE. Using the
same cohort as that described in Figure 12, serum C3 levels were assessed and found to
be lower than WT mice in older animals, although higher than WT in the younger
animals.

Significance was calculated using Mann-Whitney rank order analysis (***

p<0.0005).
Caster/Korte et al. 2013.
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Figure 14 – Renal Histology of WT and ABIN1[D485N] Mice
Renal histology in wild-type and ABIN1[D485N] mice. (A) 100X magnification of a
Periodic acid-Schiff (PAS) stained kidney section from a 3-4 month old wild-type (WT)
mouse. (B) A comparative 100X PAS image shows that at 3-4 months the
ABIN1[D485N] mouse kidneys display mesangial hypercellularity, matrix expansion and
capillary loop thickening as compared to WT mouse kidneys. (C) 100X magnification of
a Periodic acid-Schiff (PAS) stained kidney section from a 5-6 month old wild-type (WT)
mouse. (D) A comparative 100X PAS image shows that at 5-6 months the
ABIN1[D485N] mouse kidneys display severe mesangial hypercellularity, matrix
expansion and “wire loops” (arrow) compared to WT mouse kidneys.
Caster/Korte et al. 2013.
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Figure 15 - ABIN1[D485N] Mice Exhibit Interstitial Inflammation
Representative 40X magnification PAS stain showing glomerular injury and extensive
interstitial immune cell infiltration (arrow) observed in 5-6 month ABIN1[D485N] mouse
kidneys.
Caster/Korte et al. 2013.
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Figure 16 - ABIN1[D485N] Mice Exhibit Interstitial Fibrosis
Representative 40X magnification of Masson's trichrome staining showing examples of
tubuleinterstitial fibrosis, glomerular fibrosis and crescent formation (arrow) and immune
cell infiltration (lower right corner) in 5-6 month ABIN1[D485N] mouse kidneys.
Caster/Korte et al. 2013.
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Figure 17 - ABIN1[D485N] mouse glomeruli display mesangial and subendothelial
deposits.
(A) TEM image of WT mouse kidney (large arrow, erythrocyte; small arrow, endothelial
cell). (B) Minimal mesangial expansion and immune deposits (small arrows) in a TEM
image of a 4-month-old ABIN1[D485N] mouse kidney. Podocyte foot processes are
intact. The large arrow points out a monocyte in a capillary. (C) Extensive mesangial
expansion and immune deposits (small arrows) in a TEM image of a 6-month-old
ABIN1[D485N] mouse kidney. The large arrow points out a monocyte in a capillary. (D)
Example of subendothelial immune deposits (long small arrow), areas of podocyte
effacement (short small arrow), and mesangial immunoglobulin deposits (large arrow) in
a 6-month-old ABIN1[D485N] mouse kidney.
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Caster/Korte et al. 2013.

demonstrating moderate mesangial expansion and small electron dense deposits in the
mesangium (small arrows). Podocyte foot processes are intact. The large arrow points
out a monocyte in a capillary. TEM in Figure 17c shows extensive mesangial expansion
and mesangial deposits in a 6 month old ABIN1[D485N] mouse kidney (small arrows).
The large arrow points out a monocyte in a capillary. Figure 17d shows a TEM from a 6
month old ABIN1[D485N] mouse demonstrating subendothelial (long, small arrow) and
mesangial (large arrow) electron dense deposits and focal foot process effacement (short,
small arrow).
Figure 18 shows immunofluorescence (IF) images of 5-6 month ABIN1[D485N]
kidneys demonstrating IgG, IgA, IgM, C3, and C1q deposition along capillary loops and
in the mesagium. IF from 3-4 month old ABIN1[D485N] mouse kidneys showed mild
deposition of immunoglobulin and complement within the mesangium (not shown).
Our results show that loss of ABIN1 function in NF-κB activity is associated with
the development of proteinuria and proliferative glomerulonephritis with features typical
of class III and IV LN. Those changes become progressively worse between 3 and 6
months, at which time they are associated with low serum C3 levels. From our animal
data, we postulated that genetic alterations in ABIN1 leading to dysregulation of NF-κB
and MAPK activation could be involved in the development of LN. This hypothesis led
us to evaluate SNPs in the gene for ABIN1, TNIP1, in SLE patients with and without LN.

Association of TNIP1 SNPs and Human Lupus Nephritis
To investigate a clinical relevance for ABIN1 dysfunction in human lupus nephritis (LN),
5 SNPs in TNIP1 previously associated with autoimmune diseases, including SLE, were
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Figure 18 - Deposits in ABIN1[D485N] glomeruli contain complement factors and
immunoglobulins.
The panels show examples of the immunoﬂuorescence staining that was observed for the
different labeled complement factors and immunoglobulin subtypes in kidneys from 5 to
6-month-old ABIN1[D485N] mice. No signiﬁcant immunoﬂuorescence was observed
for age-matched WT mice.
Caster/Korte et al. 2013.
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genotyped in a total of 16,999 individuals of European-ancestry (EA), African American
(AA), Asian, Gullah and Hispanic as described in Chapter 2 (Table 7) ([65]). After
applying quality control assessment, we studied 15,864 individuals consisting of 3,089
SLE cases with LN, 4,308 SLE cases without LN, 1,097 SLE cases with unknown status
of LN, and 7,492 healthy controls (Table 8). To evaluate evidence for genetic association,
we performed single-marker logistic regression analysis adjusting for gender and global
ancestry estimates. Comparing SLE cases with lupus nephritis to SLE cases without LN
(case/case analysis) showed strong associations surpassing the Bonferroni corrected
significant threshold P < 0.01 at rs7708392 in EAs (P = 3.66 x 10-4, odds ratio (OR) =
1.22) and rs4958881 in AAs (P = 8.47 x 10-3, OR = 1.22) (Table 9). No SNPs reached the
Bonferroni corrected significant threshold in other populations. Analysis of SLE cases
with LN versus healthy control subjects confirmed the validity of our case only analysis
(rs7708392 in EAs: P = 1.82 x 10−11, OR = 1.44; rs4958881 in AAs: P = 4.43 x 10-3, OR
= 1.20). Overall, our results indicate that polymorphisms in the region of TNIP1 are
associated with LN in EAs and AAs.

4.3 – Discussion

Here I show that a knock-in mouse expressing an ABIN1 mutant,
ABIN1[D485N], with impaired negative regulation of NF-κB, developed progressive,
proliferative glomerulonephritis with histologic features of class III and IV human lupus
nephritis (LN), and 2 SNPs of the ABIN1 gene, TNIP1, are significantly associated with
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Healthy Controls

SLE Cases with Lupus
Nephritis

SLE Cases without Lupus
Nephritis

SLE Cases with Unknown
Lupus Nephritis Status

Male

Female

Unknown Gender

European
American
AfricanAmerican
Asian
Gullah
Hispanic
Total

# of Samples

Population

Table 7 - Sample summary before quality control adjustments.

8066

3818

1243

2306

699

1642

6403

21

3462

1893

636

663

270

723

2733

6

2676
286
2509
16999

1348
131
887
8077

561
70
702
3212

633
80
823
4505

134
5
97
1205

296
34
227
2922

2380
252
2279
14051

0
0
3
30

Caster/Korte et al. 2013.
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Healthy controls

SLE Cases with Lupus
Nephritis

SLECases without Lupus
Nephritis

SLE Cases with Unknown
Lupus Nephritis Status

Male

Female

EuropeanAmerican
AfricanAmerican
Asian
Gullah
Hispanic
Total

# of samples

Population

Table 8 - Sample Summary Following Quality Control Adjustments

7427

3491

1129

2161

646

1495

5932

3338

1811

709

704

234

695

2643

2525
275
2299
15864

1260
123
807
7492

529
70
652
3089

610
79
754
4308

126
3
88
1097

253
33
207
2683

2272
242
2092
13181

Caster/Korte et al. 2013.
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nephritis.

Table 9 - The association results comparing SLE cases with lupus nephritis versus SLE cases without lupus

human LN. A role for NF-κB in the incidence and severity of LN was suggested
previously by the correlation of enhanced NF-κB protein expression in disease kidney
sections or reduction of disease phenotypes in animal models after administration of
compounds that indirectly inhibit NF-κB signaling [30–34]. Although the mechanisms
regulating those effects of NF-κB on LN have not been determined, these data provide a
potential mechanism for NF-κB dysregulation in some patients with LN.
K63 and linear polyubiquitin conjugation mediates a number of protein-protein
interactions required for activation of the IκB kinase (IKK) complex and hence NF-κB
transcription [56,174–176]. ABIN1 contain a polyubiquitin binding domain (UBD) that is
also present in NEMO, termed UBAN (Ubiquitin-Binding domain in ABIN proteins and
NEMO) [62]. . The UBAN in ABIN1 contains a highly conserved region consisting of
amino acids 472-480 in humans and 485-495 in mice [62]. The Asp to Asn mutation at
this conserved residue 485 (mouse) or 472 (human) of the UBAN renders ABIN1
incapable of binding recombinant Lys63 and linear polyubiquitin chains and
polyubiquitinated NF-κB activators from cell lysates [44,50,51,53,62]. We previously
reported that ABIN1[D485N] knock-in mice have enhanced NF-κB signaling in B cells
and bone marrow-derived macrophages and developed a SLE-like autoimmune disease,
with enlarged spleens and lymph nodes, elevated levels of pathogenic immunoglobulins,
and antinuclear antibodies in the serum as early as 4 months of age [53]. The present
report shows that those mice develop proteinuria by 3-4 months of age,
hypocomplementemia by 5-6 months, and renal histologic abnormalities including focal
and diffuse glomerular hypercellularity involving both endocapillary and mesangial cells,
increased mesangial matrix accumulation, “wire loop” thickening of glomerular capillary
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walls, immunoglobulin (IgG, IgA, and IgM) and complement deposition in a mesangial
and capillary loop pattern, and mesangial and subendothelial electron dense deposits by
electron microscopy. Those findings suggest that ABIN1[D485N] knock-in mice provide
a model of human SLE, including the development of class III/IV LN. Our model
indicates that SLE and LN can be initiated by disruption of ABIN1 NF-κB inhibitory
function, at least in part, in B cells. Another recent report showed that ABIN1-deficient
mice develop progressive lupus-like autoimmune phenotypes and glomerulonephritis
[52]. In addition to NF-κB activation, we also showed in a previous report that JNK and
p38 MAPK signaling was enhanced after stimulation with TLR agonists in B cells, bone
marrow-derived macrophages (BMM), and dendritic cells isolated from ABIN1[D485N]
mice [53]. A role for enhanced MAPK signalling in the development of
glomerulonephritis (GN) has been suggested in several reports [177–180]. Stambe et al.
showed that there was enhanced active p-p38 MAPK in glomeruli, tubules, myofibroblast
and infiltrated neutrophils and macrophage in kidney biopsies from patients with
different types of proliferative GN, including class III/IV LN and that elevated p-p38
MAPK correlated with renal dysfunction and histopathology [180]. The same group
showed in a separate study that administration of a specific p38 MAPK inhibitor
prevented renal injury and renal function loss from anti-glomerular basement membrane
(GBM)-induced GN in rats [179]. Another report showed that proteinuria and glomerular
cell proliferation-induced by anti-GBM was dependent on JNK activity in bone-marrow
macrophages [177]. Taken together, the present study and the previous reports support
the hypothesis that loss of ABIN1 K63 and linear polyubiquitin binding results in
increased NF-κB and MAPK activity and participates in the development of SLE and LN.
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Variants in the ABIN1 gene TNIP1 have been reported in SLE patients,
suggesting a role for ABIN1 in human autoimmune disease [65,67,68]. Gateva et al.
showed an association for a TNIP1 variant (rs7708392) in European-Ancestry American
and Swedish SLE patients [67]. Han et al. also reported a TNIP1 variant (rs10036748) in
a Chinese Han SLE population [68]. This SNP also showed significant association with
European population, and the frequency (77%) was much higher in the European
population than in the Chinese population (26%) [68]. Both of these variants are in noncoding regions of TNIP1, and the functional consequence and association with LN were
not reported. The associations of those TNIP1 variants were also replicated in Japanese
(rs7708392) and Chinese Han (rs10036748) populations [181,182]. There was a stronger
association for rs7708392 with LN in the Japanese population [181]. A replicate study of
rs7708392 and rs10036748 in a southwest Chinese SLE population found a weak
association, but as for the Japanese population, a significant association for rs7708392
with LN in their SLE population was apparent [69]. Consistent with those previous
reports, the current study found association (P = 3.66 x 10-4, odds ratio (OR) = 1.22) for
rs7708392 when comparing American SLE patients of European-Ancestry with LN vs.
those without LN, but this association was not significant in African, Asian or Hispanic
American cohorts. The discord for the finding in our Asian cohort and the reported
finding in southwest Chinese and Japanese populations with regards to LN association
may be explained by the composition of our Asian population of 1012 total patients,
which was 90% Korean. The present report also identified association for another TNIP1
variant (rs4958881) (P = 8.47 x 10-3, OR = 1.22) in African American SLE patients with
LN vs. those without LN. rs4958881 was previously reported to be associated with
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systemic sclerosis (SSc), but not SLE [71]. Additionally, ABIN1 expression was
decreased in SSc skin lesions and in dermal fibroblast from SSc patients, compared to
controls, and transgenic expression of ABIN1 abrogated matrix protein expression
induced by inflammatory cytokines in fibroblast from SSc patients [71]. This suggests
that the rs4958881 variant could result in lower renal expression of ABIN1 in LN,
leading to increased mesangial cell matrix production typically seen in class III and IV
LN in humans [10] and found in the ABIN1[D485N] knock-in mice.
In summary, these data suggest that mutations in ABIN1 represent a new genetic
basis for LN through the novel pathophysiologic mechanism of aberrant regulation of
NF-κB and MAPK activity (Figure 19). This is supported by knock-in mice expressing a
mutation of ABIN1 with loss of NF-κB and MAPK inhibitory function and a strong
association of a novel TNIP1 polymorphism and LN in a SLE patient population with a
higher incidence of LN. Our findings support an association between polymorphisms in
TNIP1 and the development of LN. This mouse model closely replicates the human
disease and, therefore, potentially serves as an effective tool to study diagnostic and
therapeutic strategies for LN.
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Figure 19 - ABIN1 aberrant regulation of NF-κB and MAPK signaling in LN.
Pro-inflammatory gene activation is mediated by activation of the upstream I kappa B
kinase (IKK) complex or MAPK kinases (MKK) activation of JNK or p38 MAPK. IKK
and MKKs are activated by an Inflammatory Activating Complex (IAC) consisting of
IRAKs, TRAFs, RIPs, and TAK1, among others. ABIN1 binds to K63-linked and linear
polyubiquitin chains and inhibits components of the IAC or IKKγ.
Caster/Korte et al. 2013.
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CHAPTER V

ABIN1 DETERMINES THE SEVERITY OF ANTIBODY-MEDIATED
GLOMERULONEPHRITIS THROUGH A NOVEL PODOCYTE-NEUTROPHIL AXIS

5.1 – Introduction

Proliferative glomerulonephritis (GN) is an important cause of end-stage renal
failure [183]. The current paradigm for the pathogenesis of GN is that immunoglobulin
deposition in the glomerulus, in the form of immune complexes or autoantibodies against
constituents of the glomerulus, initiates a proinflammatory response through Fc receptor
(FcR) ligation and activation of the complement cascade, leading to immune cell
recruitment and activation. Mesangial cells respond to immunoglobulin and complement
by regulating the glomerular microenvironment through the production of various
cytokines and chemokines, resulting in increased endothelial cell expression of adhesion
molecules that recruit and activate leukocytes [15,18]. Although inflammatory injury
leads to podocyte dysfunction, the response of podocytes to immunoglobulin and/or
complement deposition and their contribution to the inflammatory response are poorly
understood, and only a few authors have published work to expand this field [22,23].
Although limited in number, these studies suggest that podocytes have the potential to
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actively participate in the modulation of the immune response. If podocytes can be
shown to provide the cytokines and chemokines that influence glomerular inflammation,
this may open up therapeutic avenues never before considered.
It is well established that neutrophils are pathogenic protagonists in antibodymediated GN, although recent effort has focused on cells that function in a more classic
immunoregulatory role, such as monocytes, B-cells, T-cells, and dendritic cells [23–29].
Neutrophil granules contain both reactive oxygen species and proteases that cause injury
to vascular tissue when released, and the glomerulus is in the unique situation to be
constantly patrolled by neutrophils [25–28].

Still, direct injury of podocytes by

neutrophils has not previously been evaluated.
As highlighted previously, NF-κB activation is associated with GN and is
important to podocyte response to proinflammatory stimulation [35–37]. Inhibition of
NF-κB signaling protects against development of disease, at least in part, through reduced
expression of cytokines that are transcriptional targets of NF-κB [30,33,34,38]. Chapter
IV of this dissertation as well as previous work describe ABIN1 as an important inhibitor
of NF-κB activation [54,55,59]. It characterizes mice expressing the ubiquitin bindingdeficient mutant, ABIN1[D485N], as prone to spontaneous immune hyperactivation and
severe GN, which is frequently fatal by 6 months [53,184]. The work outlined in Chapter
IV describes a pathogenic state in which ABIN1 fails to inhibit NF-κB stimulation to
allow rampant hyperactivation and uncontrolled inflammation.

It did not define a

specific cellular mechanism or tissue-specific interaction which could be a target for
therapeutic pharmacologic intervention, or allow current therapies to be better targeted to
affected tissues for reduced side effects.
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The present study used nephrotoxic sera (NTS) containing antibodies directed
against the glomerular basement membrane (GBM) to induce a well-characterized model
of nephrotoxic nephritis (NTN). NTS-induced damage in wild-type and ABIN1[D485N]
mice is used to address the hypothesis that NF-κB-dependent proinflammatory mediator
production by intrinsic renal cells, particularly podocytes, contributes to initiation and
progression of GN through enhanced retention and activation of neutrophils. The model
of acute NTN mimics the pathogenesis of a number of human glomerular diseases,
including lupus nephritis and rapidly progressive GN, and anti-GBM GN is associated
with in vivo activation of NF-κB [38,185]. This chapter describes a role for glomerular
cell ABIN1 regulation of NF-κB in antibody-mediated GN, and we describe a novel
pathogenic interaction between podocytes and neutrophils within the glomerulus.

5.2 – Results

ABIN1[D485N] mice exhibit exaggerated and localized renal disease compared to
WT
Chapter IV describes that ABIN1[D485N] mice spontaneously develop severe
GN beginning at 3-4 months of age that progresses by 5-6 months [184]. To define the
effects for this ABIN1 mutation on intrinsic glomerular cells, NTS-induced injury was
induced at 6 weeks of age, immediately after weaning.

Figure 20 shows urine

albumin:creatinine (mg/g) ratios (UAC) from ABIN1[D485N] and WT mice obtained
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Figure 20 – ABIN1[D485N] Mice More Sensitive to NTS than WT.
NTS administered to mice at 6 weeks of produces significantly different levels of
proteinuria, with ABIN1[D485N] animals exhibiting 9x the level of urine albumin.
Normal serum (NS) served as a control and did not induce proteinuria. Injection of ontrol
sera (NS), did not change proteinuria in either WT or ABIN1[D485N] mice. (n = 6-12
per condition) Student’s T-test was used to compare values between two groups.
Korte, unpublished.
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just prior to NTS tail vein injection (0 hour) and 24 hours after NTS injection. The 0
hour UAC of WT and ABIN1[D485N] mice were not different, and administration of an
equal amount of normal serum immunoglobulin did not increase the 24 hour UAC above
unstimulated levels in either WT or ABIN1[D485N] mice.

Both WT and

ABIN1[D485N] mice demonstrated a significant increase in UAC 24 hours after NTS
administration, but the increase in UAC was 9-fold higher in ABIN1[D485N] mice
compared to WT mice.
To separate the effects of ABIN1[D485N] on systemic immune activation and on
intrinsic renal cells, NTN was induced in chimeric mice, as described in materials and
methods.

Figure 21 shows that NTS-induced proteinuria was similar in WT mice

whether transplanted with WT or ABIN1[D485N] mouse bone marrow. Again, as shown
in Figure 20, ABIN1[D485N] mice showed significantly greater albuminuria than wildtype mice, and that proteinuria was similar in ABIN1[D485N] mice transplanted with
WT or ABIN1[D485N] mouse bone. Thus, differences in proteinuria in chimeric mice
were due to the host genotype, not to the immune system genotype. This conclusion was
supported by serum expression of common immune mediators. Figure 22 shows that no
significant differences between WT and ABIN1[D485N] mice in serum levels of G-CSF,
GM-CSF, IL1α/β, IL2, IL3, IL4, IL5, IL6, IL12p70/p40, TNF-α, KC, MCP-1, MIP1α/β,
or RANTES were observed.
To examine the local glomerular inflammatory response to NTS, the number of
CD45 and myeloperoxidase (MPO) positive leukocytes infiltrating glomeruli was
determined at 2 hr and 24 hr after NTS administration by immunohistochemistry (IHC).
CD45 is expressed on all leukocytes, while myeloperoxidase (MPO) is highly expressed
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Figure 21 - Bone Marrow Transplant Suggests Host Genotype is an Important
Factor in Response to NTS
Bone marrow transplant using ABIN1 WT hosts and either WT or ABIN1[D485N] bone
marrow (n=10 each) produced no change in proteinuria at 13 weeks 24 hours post-NTS.
Likewise, ABIN1[D485N] hosts did not respond differently due to immune genotypes
(n=5 each), however the host genotype was related to a significant change in proteinuria
severity following NTS administration. ANOVA was used to compare values between
the 4 conditions.
Korte, unpublished.
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Figure 22 - Serum Cytokine Analysis of WT and ABIN1[D485N] Mice before and
following NTS
Serum cytokine expression was relatively unchanged between ABIN1 WT and
ABIN1[D485N] animals. Black corresponds to lower relative expression and increasing
red corresponds to increasing expression of an individual cytokine within the four
conditions. (n = 4 per condition)
Korte, unpublished.

103

in neutrophil azurophilic granules, modestly expressed in monocyte lysosomes, and lost
from tissue macrophages[186]. At 2 hours, WT mice expressed an average (± 95%
confidence interval) of 1.44 (±0.28) CD45 positive cells per glomerulus while
ABIN1[D485N] mice had 2.31 (±0.12) (Figure 23). At 24 hours, WT mice glomeruli
decreased to 1.10(±0.36) CD45 positive cells per glomeruli while ABIN1[D485N]
increased slightly to 2.33 (±0.29) cells per glomeruli (Figure 23). Likewise, WT mice at
2 hours expressed 0.60 (±0.13) MPO positive cells per glomerulus while ABIN1[D485N]
mice had more than twice the MPO positive cells with 1.34 (±0.19) (Figure 23). At 24
hours, MPO positivity of WT mice glomeruli descreased to 0.23 (±0.11) MPO positive
cells while ABIN1[D485N] maintained 0.95(±0.35) cells per glomeruli (Fig. 1e, p >
0.05). Representative images are shown in Figure 24.
Structural and ultrastructural characteristics of NTS challenged ABIN1[D485N]
and WT mice were assessed by light microscopy, transmission electron microscopy
(TEM), and WT-1 IHC. Blinded analysis of Periodic acid–Schiff (PAS) stained kidney
sections showed no differences in mesangial cellularity between WT and ABIN1[D485N]
mice that received control serum or NTS (n=5 per condition) (Figure 25 and Figure 26).
Mesangial matrix was significantly increased only in ABIN1[D485N] mice that received
NTS. Endothelial cell and podocyte changes were assessed using TEM (Figure 27).
Endothelial cells show a typical ultrastructure without obvious signs of pathology.
Podocytes showed prominent foot process effacement and slit diaphragm loss that was
diffuse in ABIN1[D485N] mice, but focal in WT mice. Glomerular expression of the
podocyte nuclear marker, WT-1, typically decreases in GN, and that decrease
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Figure 23 - CD45-positive and MPO-positive Cell Influx into Glomeruli
Immunohistochemistry was used to assess influx of general leukocytes (CD45+ cells) and
neutrophils with other minor staining (MPO+ cells) at both 2 hours and 24 hours post
NTS administration. The result was increased CD45 and MPO staining at both time
points for ABIN1[D485N] expressing mice. (n = 4-5 per condition and 30 glomeruli per
sample)
Korte, unpublished.
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Figure 24 - Representative Images for Immune Cell Influx into Glomeruli Post-NTS
These representative images provide examples of what was described in Figure 23.
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Figure 25 – Histological Analysis of PAS-stained Sections
Blinded analysis of PAS-stained sections of mouse kidney cortex 24 hours following
administration of either NS or NTS found only minor differences. All conditions were
statistically identical to ABIN1 WT animals given control serum (NS), with the exception
of a slight elevation of matrix expansion in ABIN1[D485N] mice treated with NTS. (n =
5 per condition with 30 glomeruli counted per sample.) Student’s T-test compared values
between two groups.
Korte, unpublished.
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Figure 26 - Representative Images for Histological Analysis of Glomeruli Following
NTS
These representative images provide examples of what was described in Figure 25.
Korte, unpublished.
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Figure 27 - Ultrastructural Analysis of NTS-induced Changes to Glomerular
Basement Membrane
Changes to the glomerular podocyte were noted 24 hours following NTS administration.
(a) TEM of ABIN1 WT glomeruli 24 hours post-NTS showed minor foot process
effacement. (b) ABIN1[D485N] mice show massive foot process effacement at 24 hours
post-NTS. Representative images highlight this discrepancy. Endothelial cell changes
and basement membrane thicken were not widespread. Scale bar represents 500nm.
Korte, unpublished.
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corresponds to increased proteinuria and worsening renal function[187]. Figure 28 shows
a significant reduction in WT-1 stained nuclei per glomerular section in ABIN1[D485N]
mice, compared to WT, both at endogenous levels using normal sera as well as 24 hours
following anti-GBM administration. Representative images are shown in Figure 29.
To determine production of mediators of inflammation by glomerular cells,
glomeruli were purified from renal cortex by sieving, RNA was extracted, and expression
levels of specific transcripts were determined using a custom qRT-PCR analysis. Genes
included in this analysis were documented previously as contributing to GN either
directly or as biomarkers and included adhesion molecules (VCAM1, ICAM1),
profibrotic/proinflammatory mediators (TGFβ1, C1qB, C3, CD74, EGF), interferons
(IFNα1, IFNγ), chemokines and cytokines (MCP-1, CCL5, CXCR7, TNF-α, IL1α,
IL12b, IL17a), cytoskeletal/matrix proteins (MYH9, MMP2, MMP7, TIMP2), or NF-κB
pathway proteins (RELa, NF-κBiα, IRAK1, NF-κBiζ, NF-κB1). Figure 30 displays the
differences in glomerular gene expression between WT and ABIN1[D485N] mice 24
hours after NTS administration. mRNA expression of a number of proinflammatory
cytokine and adhesion proteins was significantly increased in ABIN1[D485N] mouse
glomeruli.

Matrix metalloproteinase 7 (MMP7) exhibited a 40-fold increase in

ABIN1[D485N] mouse glomeruli, compared to WT. Other notable anti-GBM-induced
increases in ABIN1[D485N] mouse glomeruli included VCAM1 (3.00 fold), IL1α (13.21
fold), IL17α (2.14 fold), TNF-α (5.88 fold), CCL2/MCP-1 (1.97 fold) and EGF (1.98
fold).
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Figure 28 – WT1-staining per Glomeruli
Wilms Tumor 1 (WT1) is a nuclear marker of mature podocytes. Glomerular WT1
staining following control (NS) or NTS treated animals represents podocyte loss.
ABIN1[D485N] mice exhibited a lower WT1 positive cell count per glomeruli than
ABIN1 WT under either control or damaged conditions. (n = 4 per condition, with 30
glomeruli counted for each sample) Bars represent SEM. T-test was used to compare
values between two groups. (**p<0.01, ****p<0.0001)
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Figure 29 - Representative Images for WT1 Staining
These representative images provide examples of what was described in Figure 28.
Korte, unpublished.
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Figure 30 – Expression of Proinflammatory Markers from Isolated Glomeruli from
WT and ABIN1[D485N] Mice
Isolated glomeruli from WT or ABIN1[D485N] kidneys showed marked transcriptional
changes in a number of proinflammatory cytokines, chemokines and adhesion molecules.
GAPDH served as a housekeeping gene and Student’s T-test was used to compare
between two groups. (n = 4 per condition)
Korte, unpublished.
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Loss of ABIN1 ubiquitin binding function in podocytes results in excess production
and secretion of NF-κB targeted proinflammatory mediators.
Previous studies suggested NF-κB activation plays a role in development of GN
and in podocyte dysfunction [30,33,34,38,184]. To determine if ABIN1 regulates NF-κB
activation and proinflammatory responses in podocytes, changes in NF-κB-dependent
gene expression were assessed in WT and ubiquitin binding null ABIN1[D472N]
expressing podocytes following 3-hour stimulations with TNF-α. The array assessed NFκB target genes categorized as chemokines or cytokines (27), inflammatory markers (33),
immune mediators (30).

Figure 31 shows that proinflammatory NF-κB target gene

expression was upregulated in ABIN1[D472N] podocytes.

Those findings were

confirmed using single target RT-qPCR for notable genes involved in GN pathogenesis,
including MCP-1 (CCL2), IL-8, CSF2 (GM-CSF), and CSF3 (G-CSF), and significant to
at least p<0.01 at every time point (Figure 32).

Target gene expression in

ABIN1[D472N] podocytes was found to be 4-10 fold higher for each target even without
exogenous stimulation. To confirm that increased transcript results in increased protein
secretion, podocyte supernatants were collected without contamination by FBS or
exogenous TNF-α, as outlined in Materials and Methods. ELISA for MCP-1, IL-8 and
TNF-α confirmed that increased secretion of these NF-κB regulated proinflammatory
proteins correlated with increased gene expression in ABIN1[D472N] podocytes (Figure
33).

Interaction between podocytes and neutrophils in proinflammatory activation and
injury
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Figure 31 - Expression of Proinflammatory Factors in Cultured Podocytes
RT-qPCR array showed transcriptional changes similar to what was reported in isolated
glomeruli following a 3-hour stimulation by TNF-α. Notably, proinflammatory cytokines
and chemokines were expressed at higher levels in ABIN1[D472N] expressing podocytes
with or without stimulation.

GAPDH served as a housekeeping gene and Student’s T-

test was used to compare between two groups. (n = 2 per condition)
Korte, unpublished.
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Figure 32 – Single Target RT-qPCR Validation of Array Data
Validation of four cytokines noted in the array showed significant increases in expression
using single-target RT-qPCR with stimulation times ranging from 0-6 hours. Expression
of these targets was shown to be 4-10 fold higher even at basal levels in cells expressing
ABIN1[D472N]. GAPDH served as a housekeeping gene, all experiments were carried
out in triplicate. (n = 3-5 per condition) All points are significant by Student’s T-test
between WT and ABIN1[D472N] with p<0.01.
Korte, unpublished.
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Figure 33 - ELISA Quantification of Secreted Cytokines from Cultured Podocytes
Quantification of secreted proteins by ELISA showed the differences in transcript
corresponded to increased secretion of cytokines and chemokines into the cell culture
supernatant. All experiments were completed in triplicate and repeated at least 3 times.
Student’s T-test compared values between two groups. (*p<0.05, **p<0.01)
Korte, unpublished.
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Figure 23 and Figure 24 show that glomerular leukocyte accumulation is
enhanced in vivo in ABIN1[D485N] expressing mice following NTN. To determine if
ABIN1 dysfunction in podocytes was a potential mechanism for enhanced leukocyte
recruitment into the glomerulus, the ability of WT and ABIN1[D472N] podocyte
supernatants on chemotaxis of primary human neutrophils was tested (Figure 34).
Podocytes expressing WT ABIN1 produced a secretome capable of recruiting cells into a
synthetic membrane when unstimulated, and secretome from WT cells previously
stimulated with TNF-α increased this effect.

ABIN1[D472N] expressing podocytes

produced a secretome with stronger chemotactic capabilities than ABIN1 WT expressing
cells at both basal levels and when stimulated. The ability of podocyte supernatants to
stimulate neutrophil degranulation in primary human neutrophils was examined by
measuring plasma membrane CD35 (secretory vesicle marker) and CD66b (specific
granule marker) expression (Figure 35).

Although podocyte supernatants following

incubation with TNF-α induced a significant increase in CD35 and CD66b expression,
there were no differences in degranulation induced by supernatants from WT and
ABIN1[D472N] podocytes.
To determine if the increased chemoattraction and degranulation induced by
podocyte products affected podocyte integrity, the effect of neutrophil granule contents
on podocyte cytoskeletal morphology was assessed. Podocytes were cultured for 24 hr
with supernatants from primary human neutrophils stimulated without (control) or with
TNF-α/fMLF for 30 minutes, and actin stress fibers were visualized using rhodaminephalloidin staining. Both WT and ABIN1[D472N] podocytes displayed typical healthy
stress fiber structure following 24 hour incubation with control neutrophil supernatant,
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Figure 34 - Induction of Neutrophil Chemotaxis by Podocyte Cell Culture
Supernatant
Chemotaxis of primary human donor neutrophils into synthetic membranes was induced
by podocyte cell culture supernatant over control cell culture media, and stimulation of
the podocytes before washing and collection of their media resulted in greater rates of
chemotaxis. Furthermore, podocytes expressing ABIN1[D472N] were able to induce
twice the rates of chemotaxis as ABIN1 WT. (n = 3 distinct cell culture supernatants per
condition, each used to stimulated 3 different donors of primary neutrophils.) Student’s
T-test compares values between groups. (**p<0.01)
Korte, unpublished.
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Figure 35 - Induction of Neutrophil Degranulation Markers by Podocyte Cell
Culture Supernatant
Podocyte cell culture supernatant was able to induce expression of degranulation
markers, C35 and CD66b, on human primary neutrophils. No significant differences
were noted between ABIN1 WT and ABIN1[D472N] podocyte supernatant, although
podocytes stimulated before washing and collection of supernatant were able to induce
significant expression of degranulation markers on primary neutrophils. Expression of
CD35 and CD66b was quantified by flow cytometry.

(n = 3 distinct cell culture

supernatants per condition, each used to stimulated 3 different donors of primary
neutrophils.) Student’s T-test compares values between groups. (*p<0.01)
Korte, unpublished.
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including long stress fibers extending at least half the length of the cell and crossing the
nucleus, with a primarily unidirectional distribution (Figure 36).

Anisotropy is a

measurement of the angularity of the f-actin stress fibers which uses rotational statistics
to quantify changes to f-actin organization using FibrilTool which utilizes raw images
and avoids potential bias of reprocessing [84]. Figure 37 shows the anisotropy of WT
and ABIN1[D472N] podocyte stress fibers. Anisotrophy was significantly reduced in
ABIN1[D472N] podocytes, compared to WT.

TNF-α/fMLF stimulated neutrophil

supernatant caused a significant loss of stress fiber anisotropy compared to control
supernatant in both WT and ABIN1[D472N] podocytes. Each cell assessed by FibrilTool
was also examined for three additional features of podocyte morphologic alteration;
transnuclear stress fiber loss, ring formation, and actin-rich center (ARC) formation
(Figure 38). All three of these features were found to be significantly increased in
ABIN1[D472] podocytes exposed to stimulated neutrophil granules, compared to WT.
Multivariate logistical regression analysis produced odds ratios of 7.00, 3.87, and 3.85 for
transnuclear fiber loss, ring formation, and actin rich center (ARC) formation,
respectively, in ABIN1[D472] podocytes (Figure 39).

Inhibition of neutrophil degranulation reduces proteinuria in vivo
The altered podocyte cytoskeleton induced by supernatants from stimulated neutrophils
and the ability of supernatants from stimulated podocytes to induce neutrophil
degranulation suggested that release of granule neutrophil contents participates in
podocyte injury leading to proteinuria in NTN. To test this hypothesis, we utilized a
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Figure 36 - Neutrophil Granules Induce Cytoskeletal Remodeling in Cultured
Podocytes
Neutrophil granules were shown to induce major cytoskeletal remodeling of cultured
podocytes. Representative images of rhodamine-phalloidin stained f-actin show parallel
stress fibers in podocytes exposed to supernatant from unstimulated neutrophils, but loss
of both length and orientation of these stress fibers upon 24 hour exposure to supernatant
from TNF-α-fMLF stimulated neutrophils.
Korte, unpublished.
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Figure 37 - Anisotropy of Podocyte F-actin Following Exposure to Neutrophil
Granules
The loss of stress fiber orientation is quantified using Fibriltool as described in the
Chapter 2. The anisotropy of f-actin was significantly reduced by exposure to neutrophil
(PMN) granules and also in podocytes expressing ABIN1[D472N] (n=3 samples per
condition with at least 30 cells analyzed per sample).
Korte, unpublished.
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Figure 38 - Assessment of Common Morphogenic Pathologic Changes in Podocyte
Cytoskeleton
Other commonly cited morphological changes assessed were loss of transnuclear stress
fibers, ring formation and ACR formation. Representative images for each are given.
All experiments were completed in triplicate with at least 3 separate experiments
performed. Multivariate logistic regression analysis was used to compare dichotomous
outcomes of actin remodeling and accounted for both ABIN1 genotype and exposure to
granules.
Korte, unpublished.

124

Figure 39 - Odds Ratio of Genetic Effect and Neutrophil Granules on Pathologic
Podocyte Cytoskeletal Rearrangements
To properly separate the dichotomous outcomes resulting from the stimulus (neutrophil
granules) versus the ABIN1 genotype, multivariate logistic regression analysis was used
to odds ratios and clearly showed an impact of each on podocyte actin remodeling.
Korte, unpublished.
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unique TAT-SNAP-23 fusion protein to inhibit neutrophil degranulation in vivo [89,188–
190]. Both WT and ABIN1[D472N] mice treated with TAT-SNAP-23 at the time of
anti-GBM administration and 6 hours later showed a significant reduction in proteinuria
at 24 hours (Figure 40a). Although the absolute levels of proteinuria were higher in both
groups of ABIN1[D472N] mice, compared to WT, the fold reduction in proteinuria as a
response to TAT-SNAP-23 treatment was significantly lower in ABIN1[D485N] mice
compared to WT (Figure 40b).

5.3 – Discussion

In the past few years, ABIN1 has emerged as a novel physiological inhibitor of
NF-κB and a genetic factor in autoimmunity and glomerulonephritis (GN), but a
mechanistic role for ABIN1 function in GN had not been characterized [53,66,184]. In
this study, we show that transgenic disruption of ABIN1 polyubiquitin binding activity
(by mouse D485N and homologous human D472N mutation) results in enhanced
podocyte injury and proinflammatory neutrophil activation following administration of
nephrotoxic sera (NTS) containing antibodies directed against glomerular basement
membrane (GBM) in mice and proinflammatory activation of cultured human-derived
podocytes.

The current paradigm is that GN is initiated from glomerular immune

complex deposition, followed by proinflammatory activation by podocytes and other
glomerular cells, however events regulating intrinsic kidney effects are comparatively
understudied and unclearly defined [15,191]. Previous reports from our group and others
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Figure 40 - TAT-SNAP23-mediated Inhibition of Neutrophil Degranulation Reduces
Proteinuria
Inhibition of neutrophil degranulation in vivo reduces proteinuria due to NTS.

(a)

Administration of TAT-SNAP23 at 0 hours and 6 hours following administration of NTS
markedly reduces proteinuria in ABIN1 WT expressing animals, but this reduction is
muted in mutant animals. (n=6-9 per condition) (b) Fold change reduction in average
UAC following TAT-SNAP23 treatment was higher in WT mice than in ABIN1[D485N]
mice. Student’s T-test compared values between two groups.
Korte, unpublished.
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indicate that immune deposition is mediated by autoantibody reactivity to endogenous
and planted target glomerular antigens [5,192–195]. While it is presumed that these
autoantibodies are nephritogenic, to date no pathogenic mechanisms have been defined.
The NTS in vivo model was selected for our study for three reasons: (1) reports show
glomerular NF-κB activation, (2) it shares the etiology of an important type of human
GN without the requirement of presensitization of the immune system, and (3) rapid or
acute development of proteinuria in response to NTS injection may allow investigation of
the instigating pathogenic mechanism of podocyte injury [38,185,196]. Consistent with a
podocyte injury postulate, we report no remarkable mesangial cell alterations, including a
lack of mesangial cell expansion post NTS injection for both WT and ABIN1[D485N]
mice and only minimal matrix expansion. There was, however, focal podocyte foot
process effacement in WT kidneys on electron microscopy which was more pronounced
in ABIN1[D485N] mice. Loss of glomerular WT-1 staining further supported podocyte
dysfunction in α-GBM-mediated GN.

Urinary protein loss was more severe in

ABIN1[D485N] mice following administration of α-GBM. Proteinuria which was 9-fold
higher in ABIN1[D485N] mice compared to WT and there was noted enrichment of
CD45+ cells (leukocytes) and MPO staining (neutrophil azurophilic granules) in
glomeruli of NTS treated ABIN1[D485N] mice compared to WT at both 2 hours and 24
hours following NTS administration.

Interestingly, neutrophils were retained in the

glomeruli at 24 hours to a much greater degree in ABIN1[D485N] mice than in WT
which suggests either the immune system itself was mounting a stronger reaction to the
NTS or something within the local tissue was acting on resident neutrophils and other
immune cells to maintain their presence within the glomerulus. To explore the question
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of increased immune activation vs local tissue effects, bone marrow transplant produced
chimeric mice and showed no effect of immune system genotype on the severity of GN
resulting from NTS and instead suggested that the local genotype was indeed the driving
force behind increased severity of renal dysfunction in ABIN1[D485N] mice.
Differences between reactivity between 6-week old mice and 12-week old mice post bone
marrow transplant were as expected and the well-described response of C57BL/6 mice to
NTS allowed controlled glomerular damage that was neither the extreme nor the subdued
categories of responses [197,198]. These findings indicated that glomerular loss of
ABIN1 polyubiquitin binding function promotes autoantibody-mediated injury and
proteinuria and suggests podocytes may be a cause rather than an effect of these
pathogenic changes. The potential mechanism for α-GBM-induced injury likely involves
both immune and intrinsic renal tissues, but the mechanism behind their interaction is not
well understood. Thus we sought to describe the functional mechanism for α-GBMmediated injury using complementary in vivo, in vitro, and ex vivo techniques.
Glomerular immune cell infiltration and inflammation described above are
hallmarks of GN. Going back to the 1990s, studies have shown correlation of elevated
glomerular expression of NF-κB-regulated proinflammatory mediators MCP-1, TNF-α,
and IL-1α with progression of GN in rodents and humans [199,200]. Renal cortex has
previously been used to investigate renal expression changes of proinflammatory genes,
but cortex samples will contain 70-90% tubule cells and their associated mRNA
transcript, which would dampen early changes in a glomerulocentric injury like α-GBMinduced nephritis. Thus, we performed RT-PCR analysis for NF-κB target and GNassociated genes using isolated glomeruli and found a significant increase in expression
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of many proinflammatory and chemotactic transcripts, including TNF-α, MCP-1(CCL2),
and IL-1α in ABIN1[D485N] mice 24 hours after NTS injury. TNF-α is commonly
overexpressed in both serum and urine of GN patients and correlates to disease severity,
specifically in immune-complex GN, and podocytes can both produce and respond to
TNF-α through the NF-κB pathway [201–206]. Thus, TNF-α was utilized as a stimulant
to study inflammation and podocyte function relating to GN pathogenesis and ABIN1
function in vitro using human-derived cultured podocytes. Mirroring the in vivo findings,
podocytes expressing the homologous human ABIN1 ubiquitin binding mutation
(D472N) exhibit exacerbated NF-κB activation, increased MCP-1, CSF 1/2, and IL-8
mRNA expression, and amplified secretion of MCP-1, IL-8, and TNF-α.
The glomerulus has been shown to be unique among capillary beds in its ability to
recruit and retain leukocytes, allowing intrinsic renal cells a unique opportunity for
intimate interaction with immune cells, specifically neutrophils [28]. An intrarenal role
for neutrophils in the pathogenesis of human GN is implicated by their glomerular
accumulation in kidney biopsies from patients with various type of GN (including
MPGN, ANCA, LN and α-GBM disease) and inversely by reduction in disease
phenotypes with neutrophil depletion in various animal models of GN [3,207,208].
However, mechanisms for glomerular recruitment and retention of neutrophils and
neutrophil-directed injury causing proteinuria in GN have not been resolved.

The

secretome of ABIN1[D472N] expressing podocytes amplified primary human neutrophil
chemotaxis into synthetic membranes when compared to WT at both unstimulated levels
and when the podocytes had been previously stimulated with TNF-α. Furthermore, we
found that podocytes possess the ability to induce neutrophil release of specific granules
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and secretory vesicles. These granules contain bactericidal proteins that also cause
inflammatory tissue injury [209,210]. Although ABIN1[D472N] supernatant tended to
produce higher levels of degranulation markers in neutrophils than WT at endogenous
levels, this failed to achieve statistical significance. It was, however, clearly shown that
stimulated podocytes of either genotype are able to produce a secretome capable of
degranulating primary neutrophils. Thus, podocytes have the ability to both recruit
neutrophils to the glomerulus and subsequently activate their release of injurious granule
contents. To further explore this mechanism in vivo, we utilized an inhibitor of neutrophil
degranulation, the chimeric protein TAT-SNAP23, which competitively binds complexed
vesicular fusion proteins, vesicle-associated membrane protein-2 and syntaxin-4, to block
release of granules from neutrophil cytosol [188,189].

Inhibition of neutrophil

degranulation by TAT-SNAP23 resulted in marked decreases in α-GBM-mediated
proteinurea in both WT and ABIN1[D485N] expressing mice. It was interesting to note
that TAT-SNAP23 pretreatment of WT mice resulted in a 9.5-fold reduction in UAC
while ABIN1[D485N] mice only exhibited a 2.6 fold reduction. This is further evidence
that the genotype of the intrinsic renal cells, specifically podocytes, is an
underappreciated pathogenic factor in glomerular maintenance and protection from
immune-mediated damage.
The interaction between podocytes and neutrophils is not one-sided and proper
ABIN1 function within podocytes was shown to be of great importance for limiting
pathogenic podocyte responses following an insult. Actin regulation is paramount in slit
diaphragm maintenance and renal function, and disorganization of actin stress fibers is a
classic sign of podocyte damage [211–215].
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Neutrophil granules clearly induce

remodeling of cultured podocyte actin fibers shown by a reduction in the anisotropy of
podocyte actin fibers, as ABIN1[D472N] expressing podocytes exhibited stress fibers
which were significantly less organized than WT when subjected to either control
neutrophil supernatant (no or few granules) or neutrophil supernatant fully degranulated
by 30 minute exposure to TNF-α/fMLF (high granule concentration).

Furthermore,

additional metrics of podocyte cytoskeletal rearrangement reinforced the anisotropy
findings, including loss of transnuclear stress fibers, ring-like actin formation, and ARC
formation [214,216–219]. Multivariant logistical regression of phenotype frequency was
used to determine statistical certainty of the dichotomous outcome and clearly showed
that podocytes expressing ABIN1[D472N] were more likely to produced aberrant actin
structures under control conditions and that development of these structures was even
more frequent following 24 hours of exposure to a degranulated neutrophil supernatant.
In total, actin rearrangement was strongly associated to ABIN1 genotype in cultured
podocytes in a way that induced pathologic changes, both under stress and at baseline,
which would promote a greater propensity for worsening disease both before and after a
nephrotoxic insult.
When considering that podocytes can both recruit and activate neutrophils and
that they undergo pathogenic responses as a result of exposure to granules released by
activated neutrophils, there is clearly support for a mechanism of GN involving a
podocyte-neutrophil axis of pathological interactions which promote proteinurea and
worsening renal function. Furthermore, functional ABIN1 seems to be important in the
regulation of podocyte responses to inhibit the damaging activity of this proinflammatory
axis. These data support a novel pathogenic mechanism for GN involving accelerated
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neutrophil recruitment and activation through proinflammatory signaling within
podocytes expressing aberrant ABIN1. These pathogenic processes described above
represent a shift from the current paradigm of GN pathology shown in Figure 4. The
findings of this dissertation are outlined graphically in the form of a healthy glomerulus
(Figure 41) and an inflamed glomerulus (Figure 42) and aim to show the importance of
podocytes in the pathogenesis of GN.
In closing, there is growing evidence for intraglomerular NF-κB activation and
genetic variation in the upstream NF-κB inhibitor ABIN1 in the pathogenesis of GN
[33,34,53,184,220,221]. Current treatment for GN involves systemic administration of
large doses of corticosteroids, immunosuppressive drugs, and/or biologic agents. Those
drugs are successful in inducing a remission of disease in only about 50% of patients, and
those drugs are associated with significant side effects [222,223]. Our findings in this
report support a role for disrupted ABIN1-mediated NF-κB activity within podocytes in
the proinflammatory activation and injury commonly described in GN. This indicates a
plausible therapeutic impact for the development of a kidney-targeted NF-κB inhibitor,
especially for treatment of GN patients with genetic variants for ABIN1 or other NF-κB
regulators.

We also show that a peptide inhibitor of neutrophil degranulation impeded

the development of proteinuria in an acute model of immune complex-mediated GN,
warranting further testing of this biologic in more severe, chronic GN models.
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Figure 41 - Healthy Glomerular Capillary
This diagram represents the glomerular capillary in a healthy glomerulus. Podocyte foot
processes are evenly spaced with well-defined slit diaphragms and the entire glomerular
basement membrane is enveloped in foot processes. Neutrophils patrol the glomerulus
constitutively but are not activated.
Korte, unpublished.
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Figure 42 - Inflamed Glomerular Capillary
This diagram represents the proposed pro-inflammatory podocyte-neutrophil axis in the
pathogenesis of glomerulonephritis. Antibody-mediated injury is augmented by NF-κBdirected inflammatory injury in the glomerulus which includes neutrophil chemotaxis,
activation and degranulation, podocyte foot process effacement and shedding, leaving
bare GBM, and pseudocyst formation. Our findings suggest that these injurious events
are mediated by loss of podocyte ABIN1 ubiquitin binding activity ensued by genetic
variants.
Korte, unpublished.
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CHAPTER VI

CONCLUSION

This work describes a novel and underappreciated cellular interaction leading to
glomerulonephritis and describes the molecular mechanism by which it occurs. It reveals
that podocytes are not the passive victims of glomerular injury as they have long been
described. Podocytes are integral players within the glomerulus and have the ability to
orchestrate changes in the molecular microenvironment which affect both themselves and
the kidney as a whole. Mechanistically, this work shows an important role of ABIN1 as a
critical inhibitor of NF-κB in glomerular disease, and suggests polymorphisms in ABIN1
could predispose a patient to a number of diseases involving enhanced NF-κB
stimulation. And finally, it has shed light on early changes which occur following
glomerular damage which initiate later pathology. Early recognition and inhibition of
these early events may reduce or prevent the development of chronic glomerular disease
in some patients.
It is my hope that this work will inspire future study in the function of ABIN1,
glomerular disease and the potential for target tissues to provide inflammatory control
mechanisms for what have long been thought to be immune-mediated diseases. To
facilitate the development of subsequent projects, I have described in detail the beneficial
function of mass spectrometry based techniques had have on discovery and outlined
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specifically how it was used in this project to identify physiologically important proteins
from complex samples. Although in vivo models invariably present the most
physiologically accurate data pertaining to any physiological process, it can be
overwhelmingly difficult or impossible to obtain pure samples from single-cell
populations. The combination of in vitro experimentation with relatively unbiased
analysis methods can elucidate the importance of low abundant factors in disease that
would certainly be lost among the noise of a more complex system.
Looking beyond this work, there are specific areas of study I hope to promote
through the publication of this dissertation. The history of ABIN1 following its initial
discovery and progressing into transgenic mouse models highlighted the complexity and
promiscuity of ABIN1 as a ubiquitin binding protein. A list of ABIN1 interacting
partners is likely vast, and will need to be identified within individual cell types before
we may begin to understand the full influence ABIN1 has on human disease and
homeostasis. Even when looking specifically at one cytokine (TNF-α) as it stimulates
one specific pathway (NF-κB), there are three different polyubiquitin linkages interacting
involving multiple proteins, all of which have different roles and all of which become
possible targets of ABIN1 binding. When considering the cell as a whole which may
contain thousands of proteins regulated by ubiquitin binding, the potential of ABIN1
activity in any cell type becomes immense. Future studies can begin by using
coimmunoprecipitation of ABIN1 and its interacting partners followed by identification
using LC-MS/MS. Tissue specific polymorphisms exhibiting increased risk of disease,
as described in the GWAS study in Chapter 4, highlight promising initial directions for
this type of discovery. Importantly, these novel interactions may involve tissue specific
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pathways which harbor potent targets for precise and high affinity small-molecule
therapeutics to treat disease only in the target tissue type, which could reduce off-target
effects of systemic therapies in use today.
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